documents incorporated reference portions definitive proxy statement registrants annual meeting shareholders filed within days conclusion registrant 's fiscal year ended december us securities exchange commission pursuant regulation securities exchange act amended incorporated reference part iii annual report extent described thereinbristolmyers squibb company index december part item business acquisitions divestitures licensing arrangements products intellectual property product exclusivity research development alliances marketing distribution customers competition pricing price constraints market access government regulation sources availability raw materials manufacturing quality assurance environmental regulation human capital management resources foreign operations bristol myers squibb website item risk factors item b unresolved staff comments item c cybersecurity item properties item legal proceedings item mine safety disclosures part ia information executive officers part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities item reserved item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data consolidated statements earnings comprehensive income consolidated balance sheets consolidated statements cash flows notes financial statements item changes disagreements accountants accounting financial disclosure item controls procedures item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedule item summary signatures summary abbreviated terms exhibit index indicates brand names products trademarks owned bms specific trademark ownership information included exhibit index end part item business general bristolmyers squibb company company bms incorporated laws state delaware august name bristol myers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger operate one segment engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis expect planned acquisitions karuna rayzebio announced fourth quarter well mirati turning point acquisitions continue position us leading biopharmaceutical company expanding targeted oncology portfolio well therapeutic areas including neuroscience principal strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discovering developing delivering transformational medicines patients facing serious diseases areas believe opportunity make meaningful difference oncology hematology immunology cardiovascular neuroscience priorities continue renewing diversifying portfolio advancing early mid latestage pipeline executing disciplined business development remain committed strengthening balance sheet returning capital shareholders discussion strategy initiatives refer item management 's discussion analysis financial condition results operationsstrategy compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers distributors specialty pharmacies lesser extent directly retailers hospitals clinics government agencies significant manufacturing operations us puerto rico switzerland ireland netherlands revenues come products following therapeutic classes hematology oncology cardiovascular immunology percentage revenues significant regioncountry follows year ended december dollars millions united states international othera total revenues revenues include royalties alliancerelated revenues products sold bmss regional commercial organizations refer summary abbreviated terms end definitions capitalized terms used throughout document acquisitions divestitures licensing arrangements acquisitions divestitures licensing arrangements allow us focus resources growth opportunities drive greatest longterm value significant business development activities included acquisition mirati completed january ii planned acquisitions karuna rayzebio announced december iii global strategic collaboration agreement systimmune announced december additional information relating acquisitions divestitures licensing arrangements refer item management 's discussion analysis financial condition results operationsacquisitions divestitures licensing arrangements item financial statements supplementary datanote alliances item financial statements supplementary datanote acquisitions divestitures licensing arrangements products intellectual property product exclusivity pharmaceutical products include chemicallysynthesized small molecule drugs products produced biological processes called biologics chimeric antigen receptor cart cell therapies small molecule drugs typically administered orally form tablet capsule although drug delivery mechanisms used well biologics typically administered patients injections intravenous infusion cart therapies administered patients intravenous infusion summary significant products including approved indications information alliance arrangements certain products refer alliances item financial statements supplementary datanote alliances inline products eliquis eliquis apixaban oral factor xa inhibitor indicated reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence following initial therapy opdivo opdivo nivolumab biological product fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen also approved multiple markets treatment nsclc melanoma mpm rcc crc various gastric esophageal cancers several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents orencia orencia abatacept biological product fusion protein indicated adult patients moderate severe active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate pomalystimnovid pomalystimnovid pomalidomide small molecule administered orally modulates immune system biologically important targets pomalystimnovid indicated patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor demonstrated disease progression within days completion last therapy yervoy yervoy ipilimumab biological product ctla immune checkpoint inhibitor yervoy monoclonal antibody treatment patients unresectable metastatic melanoma opdivoyervoy regimen approved multiple markets treatment nsclc melanoma mpm rcc crc esophageal cancer sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment patients philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate treatment children adolescents aged year years chronic phase philadelphia chromosomepositive cml new product portfolio reblozyl reblozyl luspaterceptaamt biological product erythroid maturation agent indicated treatment anemia adult patients transfusion dependent nontransfusion dependent beta thalassemia require regular red blood cell transfusions ii adult patients low intermediaterisk mds ring sideroblasts require red blood cell transfusions well iii adult patients without previous erythropoiesis stimulating agent use esanave low intermediaterisk mds may require regular red blood cell transfusions regardless ring sideroblast status opdualag opdualag nivolumab relatlimabrmbw combination nivolumab pd blocking antibody relatlimab lag blocking antibody indicated treatment adult pediatric patients years age older unresectable metastatic melanoma abecma abecma idecabtagene vicleucel bcma genetically modified autologous cart cell therapy indicated treatment adult patients relapsed refractory multiple myeloma four prior lines therapy including immunomodulatory agent proteasome inhibitor anticyclic adp ribose hydrolase monoclonal antibody zeposia zeposia ozanimod oral immunomodulatory drug used treat relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease adults treat moderately severely active uc adults breyanzi breyanzi lisocabtagene maraleucel cddirected genetically modified autologous cart cell therapy indicated treatment adult patients relapsed refractory large bcell lymphoma one lines systemic therapy including diffuse large bcell lymphoma otherwise specified highgrade bcell lymphoma primary mediastinal large bcell lymphoma fl grade b camzyos camzyos mavacamten cardiac myosin inhibitor indicated treatment adults symptomatic obstructive hcm improve functional capacity symptoms sotyktu sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicated treatment adults moderatetosevere plaque psoriasis candidates systemic therapy phototherapy onureg onureg azacitidine oral hypomethylating agent incorporates dna rna indicated continued treatment adult patients aml achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy inrebic inrebic fedratinib oral kinase inhibitor indicated treatment adult patients intermediate highrisk primary secondary post polycythemia vera postessential thrombocythemia mf augtyro augtyro repotrectinib kinase inhibitor indicated treatment adult patients locally advanced metastatic rospositive nsclc recent loe products revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicated treatment patients multiple myeloma revlimid single agent also indicated maintenance therapy patients multiple myeloma following autologous hematopoietic stem cell transplant revlimid received approvals several indications hematological malignancies including lymphoma mds abraxane abraxane paclitaxel albuminbound particles injectable suspension solventfree proteinbound chemotherapy product combines paclitaxel albumin using proprietary nab technology platform used treat breast cancer nsclc pancreatic cancer among others license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes provided rdp period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries rdp exclusivity rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives provide market exclusivity period product expires beyond patent term patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion impact generic medicines business refer competition specific aspects law governing market patent protection rdp pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovator company develop obtain regulatory approval new drug compensation least part lost patent term due regulatory review periods innovator may depending number factors apply government restore lost patent term extending expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical product company files nda medicine biological product bla filed types applications receive certain periods regulatory exclusivity nda bla compound designated orphan drug receive seven years exclusivity orphan drug indication period fda generally may approve another application drug product orphan use company may also earn six months additional exclusivity drug specific clinical studies conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity type application filed nda bla affect rdp exclusivity rights discussed chemical products competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda invalid unenforceable infringed generic product allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights medicines approved nda also receive several types rdp innovative chemical pharmaceutical product entitled five years rdp us fda approve generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear rdp period pharmaceutical drug product contains active ingredient previously approved nda approved example new formulation new route administration drug new indication basis new clinical studies may receive three years rdp formulation route administration indication marketed chemical products include eliquis pomalyst sprycel zeposia onureg inrebic camzyos sotyktu augtyro repotrectinib biologic products includes cart cell therapy products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar version may filed four years approval innovator product qualified innovative biological products receive years rdp meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda marketed biologic products include opdivo orencia yervoy reblozyl abecma opdualag breyanzi increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions may limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments among others possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed october november subject rdp regime eight years innovator received first community authorization medicinal product generic company may file maa product health authorities maa approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved rdp expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property rdp addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan patents pharmaceutical products enforceable may extended compensate patent term lost regulatory review process medicines new chemical entities generally afforded eight years rdp approved indications dosage generic copies receive regulatory approval rdp patent expirations general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well following chart shows key products together year earliest basic exclusivity loss patent rights rdp exclusivity currently estimated occur us eu japan estimated minimum market exclusivity date also sell pharmaceutical products countries however data provided countrybycountry basis individual country revenues significant outside us eu japan generally estimated minimum market exclusivity date table pertains end rdp com patent expiration respective products ptr granted situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical study data obtain marketing approval prior expiration rdp estimate minimum market exclusivity date products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate estimated minimum market exclusivity date us eup japan abecma idecabtagene vicleucel abraxane paclitaxela augtyro repotrectinibb breyanzi lisocabtagene maraleucelc camzyos mavacamtend eliquis apixabane inrebic fedratinibf onureg azacitidineg opdivo nivolumab opdualag nivolumab relatlimabrmbwh orencia abatacepti pomalystimnovid pomalidomidej reblozyl luspaterceptaamtk revlimid lenalidomidel sotyktu deucravacitinibm sprycel dasatinibn yervoy ipilimumab zeposia ozanimodo see product footnote information currently market product country region indicated abraxane us eu generics entered market japan estimated minimum market exclusivity date june aware generics entering market december b augtyro us ptr application pending granted estimated patent expiry c breyanzi us ptr application pending granted estimated patent expiry camzyos us ptr application pending granted estimated patent expiry eu spc applications pending granted estimated patent expiry would e eliquis us two patents listed fda orange book composition matter patent claiming apixaban specifically expiring formulation patent expiring challenged numerous generic companies bms along partner pfizer settled number generic companies settled generic companies continuing litigate three remaining generic companies remaining generic companies august us district court district delaware decided two challenged eliquis patents valid infringed remaining generic companies remaining generic companies appealed september us court appeals federal circuit upheld decision respect patents terms previously executed settlement agreements settled generic companies permitted date launch settled generic companies patents april subject additional challenges eu apixaban composition matter patents related spcs expire generics challenged composition matter patents related spcs various jurisdictions trials taken place scheduled take place certain european countries legal proceedings pending generic manufacturers begun marketing generic versions eliquis certain eu countries may seek market generic versions eliquis eu countries prior expiration date apixaban patents related spcs refer item financial statements supplementary datanote legal proceedings contingencies information f eu estimated minimum market exclusivity date based rdp exclusivity g onureg us estimated minimum market exclusivity date based seven years orphan drug exclusivity formulation patents covering onureg expire us eu japan us generic companies challenged formulation patents listed fda orange book litigation ongoing eu four formulation patents ep ep ep ep cover onureg pending opposition proceedings epo opposition division found three formulation patents invalid decisions appealed refer item financial statements supplementary datanote legal proceedings contingencies information h opdualag us ptr application pending granted estimated patent expiry eu spc applications pending granted estimated patent expiry bms aware orencia biosimilar market us eu japan formulation additional patents expire beyond j pomalyst us currently expect generic entry prior first quarter europe estimated minimum market exclusivity date august based rdp exclusivity japan estimated minimum market exclusivity date based method use patent k reblozyl us europe estimated minimum market exclusivity date based rdp exclusivity us ptr application method treatment patent pending granted estimated patent expiry eu spc applications method treatment patent pending granted estimated patent expiry l revlimid us part settlement natco pharma ltd natco partners affiliates natco granted volumelimited license sell generic lenalidomide us commencing march certain generic companies granted volumelimited licenses sell generic lenalidomide us beginning confidential dates sometime march volumelimited license date provided natco natco certain generics begun marketing generic lenalidomide products us pursuant volumelimited licenses addition natco generic companies granted licenses sell generic lenalidomide us without volume limitation beginning january eu japan generics entered market sotyktu us ptr application pending granted estimated patent expiry eu spc applications pending granted estimated patent expiry would japan ptr application also pending granted estimated patent expiry n sprycel us bms entered settlement agreements apotex inc certain companies regarding patents covering certain polymorphic forms dasatinib whereby generic companies launch generic dasatinib anda products september earlier certain circumstances lawsuits filed bms pending generic companies containing paragraph iv certifications seeking approval dasatinib products us eu epos opposition division upheld validity patent directed use dasatinib treat cml expires however settlement agreements certain generics already launched generic dasatinib approved indications japan composition matter patent extended treatment nonimatinibresistant cml however generic dasatinib product already launched approved indications refer item financial statements supplementary datanote legal proceedings contingencies information zeposia us ptr application pending granted estimated patent expiry p estimated minimum market exclusivity dates eu countries based uk france germany italy spain research development rd critical longterm competitiveness concentrate rd efforts following disease areas significant unmet medical needs oncology including lung bladder renal gastric esophageal head neck colorectal melanoma tumor types hematology cell therapy including multiple myeloma lymphoma chronic lymphocytic leukemia immunology including relapsing multiple sclerosis psoriasis lupus ra inflammatory bowel disease cardiovascular including cardiomyopathy heart failure thrombotic disorders fibrotic disease specifically lung liver neuroscience conditions including neuroinflammation neurodegeneration neuropsychiatry also continue analyze may selectively pursue promising leads areas rd pipeline includes potential medicines various modalities including small chemically manufactured molecules large protein moleculesalso known biologicsand also degraders tcell nkcell engagers millamolecules antibody drug conjugates cellular therapies gene therapies addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug typically includes phase phase ii phase iii clinical studies designed specifically support application regulatory approval particular indication assuming studies successful phase clinical studies involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical studies involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical studies conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate although regulatory approval typically based results phase iii clinical studies times approval granted based data earlier studies consider registrational studies significant rd programs programs may include investigational compounds phases ii iii development initial indications marketed products development additional indications formulations substantial components rd program strategy include expanding portfolio marketed products hematology immunology cardiovascular io agents first secondline therapy new indications drug development time consuming expensive risky rd process ie target identification major market approval typically takes fourteen years drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately small molecules enter phase development fail achieve regulatory approval small molecules enter phase ii development failure rate approximately approximately phase iii small molecules fail achieve approval biologics failure rate approximately phase development approximately phase ii development approximately phase iii rd expenses include costs discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support marketed products proportionate allocations enterprisewide costs acquired iprd include upfront payments contingent milestone payments connection asset acquisitions inlicense arrangements thirdparty intellectual property rights well upfront contingent milestones payable bms alliance partners prior regulatory approval rd expenses billion billion billion acquired iprd expenses million million billion manage rd programs product portfolio basis investing resources stage rd early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses drug discovery development work takes place across network stateoftheart facilities worldwide continued investment existing sites expansion manufacturing capabilities example expanded lawrenceville new jersey site opened rd facility cambridge massachusetts opening rd facility san diego california planned addition support continued investment cell therapy portfolio continue expanding manufacturing capabilities construction new stateoftheart cell therapy manufacturing facilities devens massachusetts completed well leiden netherlands libertyville illinois currently ongoing supplement internal drug discovery development programs acquisitions alliances collaborative agreements help us bring new molecular agents capabilities platforms pipeline broad earlytomid stage pipeline unique assets clinical development pipeline built coupling internal research development programs distributed research development model focused identifying supporting development disruptive innovative therapies outside company broad network external partnerships management continues emphasize leadership innovation productivity quality strategies success rd activities listed clinical studies approved indications marketed products related therapeutic area february whether listed compounds ultimately becomes marketed product depends results clinical studies competitive landscape potential products market reimbursement decisions payers manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound gets approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds hematology phase phase ii phase iii approved indications investigational compounds additional indications additional indications abecma alnuctamabmezigdomide breyanzi abecma l multiple myeloma relapsedrefractory multiple myeloma l chronic lymphocytic newly diagnosed multiple l multiple myeloma antisirp leukemia myeloma suboptimal l multiple myeloma hematologic malignancies relapsedrefractory follicular response postasct breyanzi lymphoma reblozyl bcl ldd l large bcell lymphoma relapsedrefractory marginal l ntd mds associated anemia lymphoma zone lymphoma l td mf associated anemia l large bcell lymphoma bcma nke relapsedrefractory mantle cell empliciti pomalystimnovid relapsedrefractory multiple myeloma lymphoma relapsedrefractory multiple myeloma bet inhibitor bms reblozyl empliciti revlimid relapsedrefractory nonhodgkin 's athalassemia relapsedrefractory multiple myeloma lymphoma investigational compounds idhifa cdgspt adc alnuctamab relapsedrefractory acute myeloid leukemia acute myeloid leukemia mre yla ep los med arefractory multiple inrebic cd nke investigational compounds iberdomide myelofibrosis ca kc u e egy al eid r leukemia bet inhibitor bms l multiple myeloma onureg hematologic malignancies g lcl doy il efibrosis tp heo rs pa u mto alo ing eu ns ns ct ee n ec wel mpo n ti en nd au nc ct eion acute myeloid leukemia tual targeting bcmaxgprcd car relapsedrefractory non diagnosed multiple myeloma opdivo hodgkin 's lymphoma mezigdomide advanced hodgkin lymphoma relapsedrefractory multiple myeloma l multiple myeloma kd l pomalystimnovid golcadomide multiple myeloma vd multiple myeloma l diffuse large bcell lymphoma relapsedrefractory multiple myeloma gprcd car aids related kaposi sarcoma relapsedrefractory multiple myeloma hivnegative kaposi sarcoma reblozyl transfusiondependent betathalassemia mds previously treated esa l transfusiondependent mdsassociated anemia revlimid l multiple myeloma mantle cell lymphoma mds multiple myeloma previously treated follicular lymphoma relapsedrefractory adult tcell leukemialymphoma sprycel l cml pediatric refractory cml oncology phase phase ii phase iii approved indications investigational compounds additional indications additional indications abraxane anticcr augtyro repotrectinib krazati breast solid tumors ntrk pan tumor l nsclc gastric antiilt krazati l colorectal cancer locally advanced metastatic nsclc solid tumors l nsclc opdivo metastatic breast cancer ar ldd l colorectal cancer periadjuvant muscle invasive nsclc l l metastatic castration nivolumab relatlimab urothelial carcinoma pancreatic resistant prostate cancer l stage iv nsclc adjuvant hcc unresectable pancreatic dgk inhibitor l hepatocellular carcinoma periadjuvant nsclc stage ib augtyro repotrectinib solid tumors iiia adjuvant nsclc ros nsclc helios celmod opdivo yervoy krazati solid tumors cl ar cm inu os mcl ae invasive urothelial advanced nsclc krasgc mutation jnk inhibitor investigational compounds l hcc opdivo solid tumors antictla nf probody l msihigh crc l metastatic melanoma mage tcer therapeutic stage iii unresectable nsclc l gastric solid tumors lung cancer opdualag esophageal squamous cell carcinoma nme colorectal cancer adjuvant melanoma l esophageal prostate cancer antifucosyl gm adjuvant melanoma prmt inhibitor relapsedrefractory small cell adjuvant bladder solid tumors lung cancer adjuvant esophagealgastroesophageal th gop fli itn nuh hmi ib boi irt tso r ti il di nl g u km ars rn u ev lb ae c ts u lt iti mag na e bi oo un sa r hl n c uv po om l hu p u bn prd eej vsu iv ota uhn set yim tre eala teo dm aa vt aa ng ce e dii b r cc c solid tumors nonsmall cell lung cancer l melanoma previously treated gastric cancer japan china tigit bispecific bet inhibitor bms subcutaneous nivolumab previously treated metastatic head neck gastric cancer solid tumors rhuph multiindications previously treated metastatic melanoma farletuzumabecteribulin l rcc previously treated metastatic msihigh crc ovarian cancer previously treated metastatic nonsquamous nsclc nonsmall cell lung cancer previously treated metastatic squamous nsclc previously treated metastatic urothelial cancer previously treated esophageal cancer neoadjuvant nsclc opdivo cabozantinib metastatic rcc opdivo yervoy l metastatic melanoma l mesothelioma l nsclc l rcc previously treated metastatic msihigh crc previously treated hcc l esophageal l gastric opdualag l melanoma yervoy adjuvant melanoma metastatic melanoma immunology phase phase ii phase iii approved indications investigational compounds additional indications additional indications orencia anticd sotyktu sotyktu active polyarticular jia autoimmune disease alopecia areata psoriatic arthritis early rheumatoid arthritis cd nex discoid lupus erythematosus systemic lupus erythematosus jia intravenous severe refractory systemic lupus sjgren 's syndrome jia subcutaneous erythematosus zeposia psoriatic arthritis ilcd crohns disease ra auto injector autoimmune disease investigational compounds ra intravenous nme afimetoran ra subcutaneous autoimmune disease systemic lupus erythematosus acute graft versus host disease pkc inhibitor tyk inhibitor bms investigational compounds sotyktu autoimmune disease moderatetosevere psoriasis cendakimab moderatetosevere psoriasis eosinophilic esophagitis zeposia eosinophilic gastroenteritis relapsing multiple sclerosis lpa antagonist moderatetosevere ulcerative colitis idiopathic pulmonary fibrosis progressive pulmonary fibrosis obexelimab iggrelated disease cardiovascular phase phase ii phase iii approved indications investigational compounds additional indications additional indications camzyos fxia inhibitor camzyos camzyos symptomatic obstructive hypertrophic thrombotic disorders heart failure preserved nonobstructive hypertrophic cardiomyopathy ejection fraction hfpef cardiomyopathy eliquis stroke prevention atrial fibrillation venous thromboembolism prevention orthopedic surgery investigational compounds investigational compounds venous thromboembolism treatment danicamtiv milvexian genetic dilated cardiomyopathy acute coronary syndrome myk atrial fibrillation obstructive hypertrophic secondary stroke prevention ssp cardiomyopathy heart failure preserved ejection fraction hfpef neuroscience phase investigational compounds antimtbrtau alzheimer 's disease cd nex multiple sclerosis eifb activator neuroscience faahmgll dual inhibitor neuroscience tyk inhibitor bms neuroinflammation disorders note pipeline excludes clinical collaborations development partnerships abecma seventy bio farletuzumab ecteribulin eisai rhuph halozyme magea tcer immatics milvexian janssen pharmaceuticals inc johnson johnson company opdivo yervoy opdualag japan ono pkc inhibitor exscientia reblozyl merck shp inhibitor bridgebio pharma tigit bispecific agenus obexelimab zenas biopharma japan south korea taiwan hk singapore australia trials exploring various combinations partnerrun study japan following registrational study readouts anticipated oncology immunology asset tumor trial asset disease trial krazati l nsclc tps krystal cendakimab eoe imp krazati l crc krystal sotyktu psa poetykpsa krazati l mutated nsclc krystal sotyktu psa poetykpsa yellowstone opdivo adjuvant hcc cmdx zeposia crohn 's disease induction yellowstone opdivo periadjuvant miuc cm zeposia crohn 's disease induction hematology cv asset disease trial asset disease trial breyanzi relapsedrefractory mzl transcend camzyos nhcm odysseyhcm reblozyl l td mf associated anemia independence confirmatory trial alliances enter alliance arrangements third parties development commercialization specific products drug candidates therapeutic areas focus alliances may structured codevelopment cocommercialization licensing joint venture arrangements arrangements may include upfront payments option payments develop commercialize specific asset technology payments various developmental regulatory salesbased performance milestones royalties cost reimbursements profit sharing equity investments provisions alliance arrangements lessen investment risk compounds leading revenue generating products reduce profitability marketed products due profit sharing royalty payments actively pursue arrangements view alliances important complement discovery development commercialization activities alliance arrangements contain customary early termination provisions following material breaches bankruptcy product safety concerns arrangements also typically provide termination bms without cause amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination notice period generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured bms terminates without cause sometimes bms 's right terminate without cause may exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance typically retain rights another party 's product intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations loss cash flows caused loss rights could material financial condition liquidity alliance agreements may structured terminate specific dates upon product 's patent expiration date without expiry date profit sharing payments typically expiration date royalty payments typically cease upon loss market exclusivity including patent expiration refer item financial statements supplementary datanote alliances information significant alliance agreements well alliance agreements marketing distribution customers promote appropriate use products directly healthcare professionals organizations doctors nurse practitioners physician assistants pharmacists technologists hospitals pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals refer government regulation field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information potential additional uses products provide information scientific exchange scientific congresses share information products appropriate ways including development publications response unsolicited inquiries doctors medical professionals mcos operations include several marketing sales organizations product marketing organization supported sales force responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new approved products uses well approved uses established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers specialty distributors specialty pharmacies lesser extent directly distributors retailers hospitals clinics government agencies revlimid pomalyst distributed us primarily contracted pharmacies lenalidomide risk evaluation mitigation strategy rems revlimid pomalyst rems programs respectively proprietary mandatory riskmanagement distribution programs tailored specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distributed mandatory riskmanagement distribution programs tailored meet local authorities specifications provide products safe appropriate distribution use camzyos available camzyos rems program product distribution limited rems certified pharmacies enrolled pharmacies must dispense patients authorized receive camzyos programs may vary country depending upon country design riskmanagement program product may sold hospitals retail pharmacies refer item financial statements supplementary datanote revenue gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues us business dsas substantially direct wholesaler distributor customers allow us monitor us wholesaler distributor inventory levels requires wholesalers distributors maintain inventory levels one month demand dsas including three largest wholesalers expire june subject certain termination provisions nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting reliably gather report inventory levels customers number countries outside us contract distributors support certain products services provided distributors vary market may include distribution logistics regulatory pharmacovigilance andor sales advertising promotion competition markets compete generally broadbased highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service rd new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales advancements treating cancer io therapies continue evolve rapid pace io products particularly opdivo operate highly competitive marketplace addition competing market share io products approved indications lung cancer melanoma face increased competition existing competing io products receive fda approval additional indications new io agents receive fda approval enter market furthermore therapies combining different io products io products existing chemotherapy targeted therapy treatments investigated potential expanded approvals anticipate io products continue experience intense competition another competitive challenge face generic pharmaceutical manufacturers certain countries including us eu regulatory approval process exempts generics costly timeconsuming clinical studies demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less rd researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion product 's revenue short period time expiration exclusivity rate revenue decline product varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenue decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent challenged generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity refer products intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs along ability manufacture products efficiently market effectively highly competitive environment pricing price constraints market access medicines priced based number factors including value scientific innovation patients society context overall health care spend economic factors impacting health care systems ability provide appropriate sustainable access necessity sustain investment innovation platforms address unmet medical needs central price clinical value innovation brings market current landscape alternative treatment options goals ensuring appropriate patient access innovation sustaining investment creative platforms continue explore new pricing approaches ensure patients access medicines enhancing patient access medicines priority us focused offering creative tiered pricing patient support programs optimize access protecting innovation advocating sustainable healthcare policies infrastructure leveraging advocacypayers input utilizing collaborations appropriate improving access care supportive services vulnerable patients collaborations demonstration projects important factor pricing medicines depends government regulation subject increasing international domestic efforts various governments implement strengthen measures regulate pharmaceutical market access product pricing payment us required provide discounts purchases pharmaceutical products various federal state healthcare programs federal government officials legislators continue face intense pressure public manage perceived high cost pharmaceuticals responded pursuing legislation inflation reduction act ira rules claim potentially reduce cost drugs federal government stakeholders discussion ira refer item businessgovernment regulation also required comply state laws seek additional transparency cost prescription drugs monitoring efforts states seek additional rebates limit state spending drugs light budget pressures international federal state legislative regulatory developments could create new constraints ability set prices andor impact market access certain areas discussion pricing pressure risk refer item businessgovernment regulation item risk factorsproduct industry operational risksincreased pricing pressure restrictions us abroad continue negatively affect revenues profit margins growth consolidation mcos pbms us optum uhc cvs health cvs express scripts esi also major factor healthcare marketplace pbms control nearly prescription market owned payers unitedhealthcare aetna cigna respectively mcos pbms consolidating fewer larger entities also enhancing purchasing strength share voice within market half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations pbms third parties support formulary management contracting mcos successfully compete formulary position mcos pbms must often demonstrate products offer medical benefits also cost advantages compared forms care exclusion product formulary lead sharply reduced usage patient populations due higher outofpocket costs patients consequently pharmaceutical companies compete aggressively products included formularies new products introduce compete products already market products later developed competitors possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy usually provided rebate pbm also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco pbm formularies many markets outside us operate environment governmentmandated costcontainment programs markets significant portion funding healthcare services determination pricing reimbursement pharmaceutical products subject either direct government control point care governments serving primary payer result products may face restricted access higher pocket expenses patients pricing pressures public private payers may subject assessments comparative value effectiveness existing standard care several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted mandated price cuts rebate schemes methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons andor reference pricing current standard care prices often reevaluated restricted throughout life medicine eu markets germany government set pricing restrictions launch pricing freedom subsequently limited companies may also face significant delays market access new products year elapse new medicines become available patients market additionally countries outside us regularly imposed new additional cost containment measures pharmaceuticals volume discounts cost caps cost sharing increases excess prior year costs individual products aggregated market level spending clawbacks trends accelerating recent years example germany reformed pricing reimbursement system restrain pharmaceutical spending reducing free pricing period introducing new costcontainment measures medicines based value assessment results use combination medicines japanese government continues impose price cuts outside normal repricing cycles last several years introduced new value assessment requirement medicines cut prices existence price differentials markets particularly among neighboring countries due different national pricing reimbursement conditions leads potential parallel trade flows government regulation pharmaceutical industry subject extensive global regulations regional country state local agencies federal food drug cosmetic act federal statutes regulations various state statutes regulations including newly enacted state laws regulating drug price transparency rebates drug spending laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments fda particular importance us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us regulatory review process resource intensive undertaking fda pharmaceutical company improvements efficiency process significant impact bringing new therapies patients quickly fda employ several tools facilitate development certain drugs expedite certain applications including fast track designation breakthrough therapy designation priority review accelerated approval incentives orphan drugs developed rare diseases others example recent years fda oncology center excellence oce established two projects test novel approaches efficient regulatory review oncology drugs realtime oncology review pilot program assessment aid assessment aid pilot program fda approved opdivo given three cycles platinumdoublet chemotherapy march firstline treatment adult patients resectable nsclc neoadjuvant setting approval achieved four months priority review pdufa date july develop framework concurrent review supplemental oncology applications among multiple approval authorities oce initiated project orbis project orbis earlier approvals australian therapeutic goods administration tga health canada united kingdoms medicines healthcare products regulatory agency received combination opdivo given three cycles platinumdoublet chemotherapy fda mandates drugs manufactured packaged labeled conformity cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse events use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject pdma part federal food drug cosmetic act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs ii impose certain safety related drug labeling changes iii mandate risk mitigation measures education healthcare providers restricted distribution medicines iv require companies publicly disclose data clinical studies v prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes knowingly offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement administration procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies us healthcare industry subject various governmentimposed laws regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities participate medicaid drug rebate program mdrp must pay rebates state medicaid programs covered outpatient drugs provided medicaid beneficiaries rebates based pricing data report regularly centers medicare medicaid services cms also participate health resources services administration 's b program must offer covered outpatient drugs statutorily defined covered entities b program ceiling price price calculated based mdrpreported data also participate federal government programs specify discounts certain federal government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases recent years several legislative policy proposals introduced us lower drug prices example august president biden signed inflation reduction act ira law provides government set negotiate prices select highcost medicare part beginning medicare part b drugs beginning nine years smallmolecule drugs years biological products initial fda approval ii manufacturers pay rebate medicare part b part drugs prices increase faster inflation beginning medicare part medicare part b drugs iii medicare part redesign replaces current part coverage gap discount program cgdp establishes cap outofpocket limits costs medicare beneficiaries beginning manufacturers responsible costs cap cap reached august us department health human services selected eliquis one first medicines subject governmentset prices beginning possible products could selected future years could among things accelerate revenue erosion prior expiry intellectual property protections effect reducing prices reimbursement certain products would significantly impact business consolidated results operations discussion legislation impact refer item managements discussion analysis financial condition results operationsexecutive summary addition december biden administration released proposed framework first time proposed drugs price factor determining drug accessible public therefore government could exercise marchin rights license third party manufacture comment period proposal ran february able predict whether final rule adopted along lines proposed adopted whether government would seek exercise marchin rights products proposals relating calculation best price potential executive orders focused drug pricing still debated state level multiple states pursuing government actions ballot initiatives address limit drug pricing reimbursement medicaid programs initiatives include drug importation canada attempts use ira 's referenced drug price state level statelevel proposals may also influence federal policy legislation given uncertainty surrounding adoption timing potential legislative policy administrative changes unable predict exact impact business however enacted changes could modify decrease access coverage reimbursement products impact rebates shift costs us could turn material impact business results operations activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda ec approval obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country discussion rebates programs refer item managements discussion analysis financial condition results operations gtn adjustments critical accounting policies sources availability raw materials general purchase raw materials components supplies required manufacturing products open market products purchase raw materials components supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate potential risk associated raw materials components supplies inventory management alternative sourcing strategies discussion sourcing refer manufacturing quality assurance discussions particular products manufacturing quality assurance operate manage manufacturing network consisting internal external resources manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical manufacturing processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals manage operate flexible manufacturing network minimizes unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologics cell therapy pharmaceutical manufacturing facilities located us puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increasing regulatory requirements example fda approved devens massachusetts commercial facility cart manufacturing june continue make capital investments devens massachusetts manufacturing facility cell therapy product candidates marketed products including breyanzi abecma invested manufacturing network including facilities bothell washington summit new jersey devens massachusetts leiden netherlands libertyville illinois well use thirdparty manufacturers addition expect continue modification existing manufacturing network meet complex processing standards required growing portfolio particularly biologics cell therapy biologics manufacturing involves complex processes traditional pharmaceutical operations beyond regulatory requirements many products involve technically sophisticated manufacturing processes require specialized raw materials example manufacture clinical commercial use several sterile products biologic products cart products particularly complex involve highly specialized manufacturing technologies result even slight deviations point production process may lead production failures recalls order address production constraints cart cell therapy manufacturing continue partner third party manufacturers expand supply vector investing new facilities drug product manufacturing longerterm accelerating plans transition new vector technologies dual sourcing strategy addition manufacturing sites rely third parties manufacture supply us portion active product ingredient drug substance necessary us manufacture various products including eliquis opdivo pomalystimnovid yervoy sprycel reblozyl abraxane zeposia camzyos sotyktu inrebic also expanding use thirdparty manufacturers drug product finished goods manufacturing continue shift towards using thirdparty manufacturers supply mature brands maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us reduce risk interruption manufacturing operations certain supply arrangements extend multiple years committed amounts using expected near longterm demand requirements subject change additional protection cases take steps maintain approved backup source available needed example capability manufacture opdivo drug product internally also arrangements thirdparty manufacturers meet demand opdivo drug substance drug product connection acquisitions divestitures licensing collaboration arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties intend continue enter arrangements agreements future addition liabilities could arise failure supply products agreements arrangements agreements could require us invest facilities manufacturing nonstrategic products case divestiture distribution arrangement resulting additional regulatory filings obligations causing interruption manufacturing strategic products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities maintenance planning manufacturing warehousing logistics distribution maintain records demonstrate quality integrity data technical information production processes control production processes involves established specifications standards raw materials components ingredients equipment facilities manufacturing methods operations packaging materials labeling perform tests various stages production processes raw materials drug substance final product product samples held stability ensure product meets regulatory requirements conforms standards tests may involve chemical physical analyses microbiological testing combination along analyses quality control testing provided business unitsite thirdparty laboratories quality assurance groups routinely monitor manufacturing procedures systems used us subsidiaries thirdparty suppliers help ensure quality compliance requirements met environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment occupational health safety sustainability group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis material addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters refer item financial statements supplementary datanote legal proceedings contingencies human capital management resources believe employees around world embody mission discover develop deliver innovative medicines help patients prevail serious diseases together unyielding focus patients defines culture demographics december approximately employees countries approximately employees located us excluding puerto rico located outside us supplement workforce contingent temporary workers certain specialized skilled services provided independent contractors average tenure employees approximately seven years people strategy bms global community compassionate purposedriven professionals living vision transforming patients lives science people strategy designed foster inclusive engaging work experience attract develop retain talented workforce reflects diverse cultures backgrounds experiences patients communities around world strive inspire career experiences enable people realize aspirations nurture healthy energizing flexible workplaces foster collaboration innovation cultivate inclusive environment diverse workforce everyone feels sense belonging valued unique perspectives excel pursuit science innovation patients prioritize investment enterprisewide comprehensive cohesive strategies programs policies initiatives described accelerate personal development collaboration service patients believe investments competitive advantage recruiting developing retaining future workforce drive innovation across people practices unrelenting push breakthrough science global inclusion diversity inclusion diversity id strengthen foundation bms achieve breakthroughs help us serve unmet evolving needs patients communities around world compelled longstanding commitment elevate inclusion diversity health equity drive equitable advancement outcomes global id strategy leads value inclusion one six core values regionally locally relevant strengthens human connection bring work every day discover develop deliver medicines help patients prevail serious diseases thrive culture belonging cultivates encourages inclusive engagement innovation encouraging employees around worldacross diverse cultures backgrounds experiencesto authentic selves work speak think boldly create energized environment co collaboration codesign bold ideas solutions lead improved patient outcomes patients communities colleagues industry deserve nothing less global id strategy enabled people business resource groups pbrgs operationalized organization design maintain pbrg chapters worldwide members network learn skills participate learning development events contribute global id strategy tangible way pbrgs sponsored members executive leadership team led fulltime dedicated leader reports directly member executive leadership team pbrgs include black organization leadership development bms network women cultivating leadership innovation multigenerational belonging disability advancement workplace network pride alliance organization latino achievement pan asian network veterans community network pbrg membership grown unique members across chapters countries october approximately bms employees members one pbrg global id strategy includes fiveyear inclusion diversity aspirational goals health equity commitments launched increasing diversity clinical trials globally improve efficacy safety medicines ii leveraging strengthening diversity workforce better understand unique needs preferences patients communities iii collaborating across global communities beyond improve education access ensuring partners provide culturally competent appropriate care iv driving economic empowerment communities serve investing diverse businesses enhance innovation agility within supply chain advancing aspirational goals continue advance id strategy drive equitable access outcomes patients communities globally career growth development bms enterprise learning vision build workforce capable accelerating future growth powered mindset continuous learning bms champions learning development people important asset recognize full potential achieve career aspirations drive business success aspire create future ready workforce developing critical skills needed tackle organizations pressing strategic priorities ondemand openenrollment learning journeys customized nominationbased experiences aim unlock personal potential exceptional learning experiences extensive library resources available multiple languages employees covers wide range specialized subjects employees enrolled professional manager leadership development programs tuition reimbursement offered globally eligible employees initiation desire development participate accredited highereducational programs support pbrg affiliation tour duty stretch assignment opportunities challenge people encourage take ownership skill development career advancement culture employee engagement workforce composed exceptional individuals critical mission discover develop deliver innovative medicines help patients prevail serious disease workforce focused patients embodies values integrity passion inclusion innovation accountability urgency employees fundamental mission want ensure workforce culture thrives thus routinely check engagement employees via global employee pulse survey confidential quarterly pulse survey conducted employees provided feedback employee satisfaction covered variety topics company culture values execution strategy diversity inclusion individual development among others survey results reviewed executive officers board directors analyze areas progress opportunity company level well function level individual managers use survey results implement actions activities intended increase wellbeing employees believe employee engagement initiatives competitive pay benefit programs career growth development opportunities help increase employee satisfaction tenure reduce voluntary turnover given criticality engaged motivated workforce select employee engagement goals incorporated annual bonus program metrics executives compensation wellbeing provide highly competitive compensation wellbeing offerings enable workforce deliver business strategy compensation includes market competitive base salaries annual incentives recognize reward company performance well individual results long term equity incentives focus employees longterm value creation also offer salesbased incentives special allowances peertopeer individual recognition executives substantial proportion pay variable atrisk based financial operational results delivered form equity supports alignment executive compensation program creation longterm value shareholders wellbeing committed prioritizing wellbeing workforce living life better strategy encouraging physical emotional work life financial wellbeing employees ensure global consistency local relevance competitiveness living life better 've established framework global set standards concentrated five key areas inclusive benefits mental health family care people disabilities caregivers gender preventive care framework enhances employee experience removes barriers access improves health outcomes living life better grounded science emphasizes flexibility inclusion ensuring employees support best meets individual needs right moment signature living life better programs include physical emotional work life financial programs employee health safety committed protecting workforce communities patients thereby ensuring continued supply lifesaving medicines goal ensure employees contractors visitors sites work conduct visit safely achieve rigorous application control risk mitigation measures defined health safety management system incidents near misses investigated root cause lessons learned effectively shared avoid recurrence comprehensive assurance program place objectively assess effectiveness adherence standards corrective preventive actions tracked closure provide comprehensive inhouse occupational health service primary objective ensuring workrelated illness disease identified early worker health protected range medical assessments including fitnessforduty preplacement reproductive health travel health wellness checks also conducted employees disabilities returning illness supported rigorous legally compliant accommodations process appropriate foreign operations significant operations outside us conducted subsidiaries distributors international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products bristol myers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act documents also available secs website wwwsecgov information relating corporate governance bristol myers squibb including principles integrity code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors board including board committees committee charters transactions bristol myers squibb securities directors executive officers available website usour company leadership investors captions print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsshareholder services caption addition information sustainability programs available website ussustainability caption foregoing information regarding website content convenience information contained connected website deemed incorporated reference filed sec incorporate reference certain information parts definitive proxy statement annual meeting shareholders proxy statement sec allows us disclose important information referring manner please refer information proxy statement available website investorsfinancial reportingsec filings caption within days end fiscal year item risk factors risks uncertainties described could significantly negatively affect business operations financial condition operating results including components financial results cash flows prospects reputation credit ratings future could cause trading price common stock decline significantly additional risks uncertainties presently known us risks currently consider immaterial could also impair business operations financial condition operating results cash flows following discussion risk factors contains forwardlooking statements discussed item managements discussion analysis financial condition results operationsspecial note regarding forwardlooking statements product industry operational risks increased pricing pressure restrictions us abroad continue negatively affect revenues profit margins products continue subject increasing pressures across portfolio pharmaceutical market access pricing controls required rebates discounts us eu regions around world result lower prices lower reimbursement rates smaller populations payers reimburse expect market access constraints pricing controls discounting restrictions become acute public private payers continue take aggressive steps control expenditures future revenues profit margins could negatively affected including result changes laws regulations relating pricing reimbursement pharmaceutical products including potential penalties increasing prices rate inflation new discounts fund redesign medicare part benefit government negotiationsprice controls may change determination best price establish maximum allowed pricereimbursement rate well changes relating federal healthcare programs modifying federal antikickback statute discount safe harbor ira includes number provisions intended lower costs drugs covered medicare part medicare part b limit medicare beneficiaries outofpocket spending medicare part benefit ii costcutting measures federal healthcare programs medicare medicaid mcos institutional governmental purchasers iii grant additional authority governmental agencies manage drug utilization negotiate drug prices including implementation regulation issued us federal government authorizing states private parties develop implement programs import certain prescription drugs canada sell us american rescue plan act eliminated medicaid prescription drug rebate cap starting january iv expanded utilization b drug pricing program b program v competition related placements applicable commercial medicare part formularies vi changes us federal pharmaceutical coverage reimbursement policies practices vii increased scrutiny drug manufacturers including additional review bms celgene house oversight reform committee viii reimbursement delays ix government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing x increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries xi collection delays failures pay governmentfunded public hospitals outside us xii developments technology andor industry practices could impact reimbursement policies practices thirdparty payers xiii inhibited market access due real perceived differences value propositions products compared competing products particular ira effect reducing prices reimbursements certain products could significantly impact business ira us department health human services effectively set prices certain singlesource drugs biologics reimbursed medicare part b part generally government prices apply nine years small molecule drugs years biological products following fda approval capped statutory ceiling price likely represent significant discount average prices wholesalers direct purchasers august us department health human services selected eliquis one first medicines subject governmentset prices beginning medicare price setting process began february conclude august september cms publish prices applicable ten drugs medicare program beginning january possible products selected future years could among things accelerate revenue erosion prior expiry intellectual property protections ira also requires drug manufacturers provide rebates medicare part b part medicines certain circumstances part benefit redesign replace part cgdp new manufacturer discount program beginning january ira percent cgdp discount replaced percent manufacturer discount medicare part beneficiaries met deductible incurred pocket drug costs threshold percent discount beneficiaries incurred pocket drug costs threshold new part benefit redesign manufacturers fail comply ira may subject various penalties including civil monetary penalties could significant ira continue meaningfully impact business strategies others pharmaceutical industry full impact ira business pharmaceutical industry including implications us competitor 's product selected price setting remains uncertain state level multiple states pursuing government actions ballot initiatives address limit drug pricing reimbursement medicaid programs initiatives include attempts use ira 's referenced drug price state level statelevel proposals may also influence federal policy legislation given uncertainty surrounding adoption timing potential legislative policy administrative changes unable predict impact business however enacted changes could modify decrease access coverage reimbursement products impact rebates shift costs us could turn material impact business results operations additionally manufacturers found knowingly intentionally overcharged b program covered entities could subject significant monetary penalties course past years celgene received inquiries human resources services administration regarding limited distribution networks revlimid pomalyst thalomid compliance b program part broader integration strategy alignment distribution model post acquisition celgene corporation announced beginning march would recognize two designated b program contract pharmacy locations per b program hospital lacks entityowned pharmacy although believe complied continue comply applicable legal requirements additional legal legislative changes respect b program may cause us update approach significant changes sales pricing practices regard distribution drugs b program material changes us payer channel mix could adverse effect revenues profitability addition required pay penalties applicable regulations would adverse effect revenues profitability additional information pricing pressures constraints refer item businesspricing price constraints market access may experience difficulties delays development commercialization new products ability replace revenue products lose patent protection directly dependent ability successfully commercialize new products timely manner common pharmaceutical industry bms expects sales key brand products like eliquis revlimid pomalyst sprycel abraxane decline loss market exclusivity products consequently future success highly dependent pipeline new products high rate failure inherent research development process new drugs result high risk funds invest research programs generate financial returns compounds products may appear promising development fail reach market within expected optimal timeframe experienced setbacks may continue addition product extensions additional indications may approved furthermore products indications approved us fdas accelerated approval program may contingent upon verification description clinical benefit confirmatory studies studies may successful developing commercializing new compounds products involve inherent risks uncertainties including efficacy safety concerns findings superior safety efficacy competing products ii delayed denied regulatory approvals including result difficulties enrolling patients completing clinical trials timely manner iii delays challenges producing products commercial scale excessive costs manufacture products iv failure enter implement optimal alliances development andor commercialization new products v changes regulatory approval processes policies may cause delays denials new product approvals vi preclusion commercialization due intellectual property issues disputes third parties vii failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product viii changing clinical preferences changing industry standards laws regulations competitors innovations may render new products enhancements existing products obsolete also unable predict changes laws regulatory policies occur affect business particularly pipeline new products regulatory approval delays especially common product expected rems program required us fda address significant riskbenefit issues expect certain future key products distributed us primarily rems program inability bring product market significant delay expected regulatory approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs canceled believe commercial prospects reduced may recognize material noncash impairment charges programs finally losing key molecules intermediaries compound library natural man made disaster act sabotage could negatively impact product development cycle provide assurance whether products development approved launched whether products launched commercially successful public announcement data clinical studies competitors news developments related competitors products latestage compounds may cause significant volatility stock price depending data may result adverse impact business financial condition results operations development key latestage product candidates delayed discontinued clinical study meet one primary endpoints stock price could decline significantly may adverse impact business financial condition results operations must maintain continuous flow successful new products successful new indications existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure shortterm longterm material adverse effect business results operations cash flow financial condition prospects assurance key product candidates would prove safe effective safe effective competing products even approved products become commercially successful approved indications could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain maintain patent intellectual property rights limitations use loss rights could result rapid loss sales affected products could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file countries addition patent environment unpredictable validity enforceability patents predicted certainty example eliquis generics challenged composition matter patents related spcs various jurisdictions trials taken place scheduled take place certain european countries legal proceedings pending generic manufacturers begun marketing generic versions eliquis certain eu countries may seek market generic versions eliquis eu countries prior expiration date applicable patents related spcs furthermore manufacturers innovative drugs well generic drug manufacturers may able design products around owned licensed patents compete us using resulting alternative technology absent relevant patent protection product data exclusivity period expires generic alternative versions approved marketed generic biosimilar product manufacturers well groups seeking financial gain also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject validity enforceability infringement challenges patent litigations postgrant review patent office proceedings although confident strength intellectual property rights may possible generic drug companies successfully challenge rights launch generic versions drugs prior expiration intellectual property rights example following certain adverse judicial decisions uk netherlands generic manufacturers begun marketing generic versions eliquis uk netherlands may seek market generic versions eliquis additional countries europe prior expiration patents may lead additional infringement invalidity actions involving eliquis patents filed various countries europe addition order avoid uncertainty expense litigation among reasons may decide enter settlements generic manufacturers permit generic market entry prior expiration intellectual property rights example result patent settlements generic entry revlimid united kingdom began january various european countries february similarly us following patent settlements certain companies granted volumelimited licenses sell generic lenalidomide us commencing march thereafter cases manufacturers may seek regulatory approval submitting clinical study data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation addition countries allowing manufacturers manufacture sell generic products negatively impacts protections afforded company lowerpriced generics biosimilars bms biologic products competing biologics could negatively impact volumes prices addition us congress us fda taken steps promote development approval generic drugs biosimilar biologics including providing generic biosimilar developers private right action obtain sufficient quantities drug samples reference products manufacturer order conduct testing necessary obtain approval generic biosimilar products addition december biden administration released proposed framework first time proposed drugs price factor determining drug accessible public therefore government could exercise marchin rights license third party manufacture comment period proposal ran february able predict whether final rule adopted along lines proposed adopted whether government would seek exercise marchin rights products assurance particular product enjoy market exclusivity full time period appears estimates disclosed form k assume provide financial guidance face intense competition manufacturers expect see increasing market penetration lowerpriced generic products future growth bms dependent market access uptake expansion marketed brands new product introductions new indications product extensions copromotional activities alliance partners competition keen lose exclusivity marketed brands lowerpriced generic products increasingly penetrate markets generic challenges products also arise time patents may prevent emergence generic competition products countries patent protection significantly weaker us eu political social pressure also pushed legislation measures promote use generic biosimilar products additional information see item risk factorswe could lose market exclusivity product earlier expected addition face competition new products entering market particularly io new products may lower prices ii superior efficacy benefit safety risk profiles whether actual perceived iii technological advantages may make products convenient use iv better insurance coverage reimbursement levels v effective marketing programs andor differentiating factors make harder products compete predict accuracy timing impact introduction competitive products treat diseases conditions like treated products product candidates business combinations among competitors major thirdparty payers may also increase competition products unable compete successfully competitors products marketplace could material negative impact revenues earnings could experience difficulties delays disruptions supply chain well manufacturing distribution sale products product supply related patient access could future negatively impacted difficulties delays disruptions manufacturing distribution sale products difficulties delays disruptions include product seizures recalls forced closings manufacturing plants ii failure failure vendors suppliers comply cgmp applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure supplier including sole source single source suppliers provide us necessary raw materials supplies finished goods within reasonable timeframe required quality v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products opdivo vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity changes types products produced biologics physical limitations labor disputes shortages business interruptions ix disruptions supply chain continuity including market forces recent stress global logistics natural disasters global disease outbreaks pandemics including covid acts war terrorism unforeseeable unavoidable events materially impact one facilities critical supplier addition manufacturing processes novel cellbased therapies cart cell therapies still evolving processes may complicated expensive approaches taken current future competitors ability source raw materials supplies used manufacture cart cell therapies develop consistent reliable manufacturing processes distribution networks attractive cost goods could impact future anticipated revenue gross profit cart cell therapies furthermore may face challenges sourcing raw materials supplies clinical approved commercial manufacturing logistical shipment delays factors control could prevent delay delivery product candidates marketed products patients additionally required maintain complex chain identity custody respect patient material material enters moves manufacturing process result even slight deviations point production process cart cell therapies material used cart cell therapies could result loss product regulatory remedial action could adversely affect future anticipated revenues andor profitability related cart cell therapies regulatory intellectual property litigation tax legal compliance risks litigation claiming infringement intellectual property may adversely affect future revenues operating earnings certain subsidiaries future may involved various legal proceedings including patent litigation claims patents invalid unenforceable andor cover product generic drug manufacturer third parties seek damages andor injunctive relief compensate alleged infringement patents commercial activities resolving intellectual property infringement claim costly time consuming may require us enter license agreements may available commercially reasonable terms successful claim patent intellectual property infringement could subject us significant damages andor injunction preventing manufacture sale use affected product products events could material adverse effect profitability financial condition adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product safety liability consumer protection commercial cases iii anti bribery regulations us foreign corrupt practices act uk bribery act including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v alleged failure fulfill obligations supply contracts government customers agreements relating business vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws regulations viii environmental health safety sustainability matters including regulatory actions response climate change ix tax liabilities resulting assessments tax authorities subject variety us international laws regulations currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business operating results financial condition company laws regulations control regulate key aspects business including limited market access pricing controls discounting ii tax liabilities returns payments iii imports trade restrictions iv intellectual property protection enforcement v good practice guidelines regulations vi accounting standards vii data storage privacy particularly eu us viii requirements reporting payments value transfers healthcare professionals provided federal antikickback statute ix compliance antibribery anticorruption practices us countries addition us healthcare industry highly regulated subject frequent substantial changes including result new judicial governmental decisions example congress passed food drug omnibus reform act december gave us fda additional authority require confirmatory trials underway time approval offered additional enforcement mechanism sponsors complete studies due diligence predict future federal state legislative administrative changes relating healthcare reform affect business additional information refer item businessgovernment regulation item businesspricing price constraints market access adverse outcomes legal matters could negatively affect business similarly legislative regulatory environment regarding privacy data protection continuously evolving subject significant attention regulators private parties globally regulators imposing new data privacy security requirements including new greater monetary fines penalties privacy violations jurisdictions operate passed continue propose data privacy legislation regulations failure comply current future laws could result significant penalties reputational harm could material adverse effect business results operations expectations relating environmental social governance considerations related reporting obligations expose company potential liabilities increased costs reputational harm adverse effects companys business increased focus foreign federal state local regulatory legislative bodies investors stakeholders regarding environmental policies relating climate change regulating greenhouse gas emissions carbon taxes emissions trading schemes sustainability human rights diversity inclusion equity matters disclosure regarding foregoing many may ambiguous inconsistent dynamic conflicting expect experience increased restrictions compliance costs legal costs expenses related new changing legal regulatory requirements moreover compliance legal regulatory requirements would require us devote substantial time attention matters addition may still subject penalties potential litigation laws regulations interpreted applied manner inconsistent practices moreover time time establish publicly announce environmental social governance goals commitments implementation environmental social governance goals initiatives involves risks uncertainties requires investments depends part thirdparty performance data outside control addition stakeholders may disagree companys environmental social governance goals targets objectives meet perceived meet stakeholders disagree environmental social governance goals targets objectives risk negative stakeholder reaction including proxy advisory services well damage brand reputation reduced demand products negative impacts business operations changes tax regulations could negatively impact earnings subject income taxes us various countries globally changes tax laws regulations occur significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities faced may continue face audit challenges apply tax law regulation ultimate resolution tax matters may result payments greater less amounts accrued could negative impact provision income taxes addition future earnings could negatively impacted changes tax legislation including changes tax rates tax base limiting phasingout eliminating deductions tax credits increase taxing certain excess income intellectual property revising tax law interpretations domestic foreign jurisdictions changes rules earnings repatriations changes tax laws us countries notably july october oecdg inclusive framework agreed general rules redefined jurisdictional taxation rights global minimum tax december eu member states voted unanimously adopt directive implementing pillar two global minimum tax rules giving member states december implement directive national legislation certain jurisdictions operate oecdg inclusive framework enacted legislation adopts subset rules effective january remaining rules becoming effective january rules associated legislative changes may significantly impact tax provision results operations implementation pillar two currently expected increase effective tax rate excluding specified items approximately failure third parties meet contractual regulatory obligations could adversely affect business rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing human resource finance data business unit functional services meet contractual regulatory obligations using third parties poses number risks may perform standards legal requirements example relation outsourcing significant clinical development activities innovative medicines contract research organizations ii may produce reliable results iii may perform timely manner iv may maintain confidentiality proprietary information v may incur significant cyberattack business disruption vi may subject government orders mandates require give priority government set aside preexisting commercial orders vii disputes may arise respect ownership rights technology developed partners viii disagreements could cause delays termination research development commercialization product result litigation arbitration moreover third parties located markets subject political social risks corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure critical third party satisfactorily meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practices act uk bribery act eus general data protection regulation similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences product labeling changes marketed products could result negative impact revenues profit margins pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration additional clinical trials headto head studies adverse events reports following use products longer periods time studies identify biomarkers objective characteristics indicate particular response product therapy conducted obtaining marketing approval products regulatory changes standards regarding safety efficacy labeling may result product label changes measures could reduce product 's market acceptance result declining revenues sometimes additional information new studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions mcos scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact operating results new information added products label affect risk benefit profile leading potential voluntary mandatory recalls withdrawals declining revenue well product liability claims additionally certain study results especially headtohead studies could affect products formulary listing could also adversely affect revenues addition safety efficacy concerns raised third party 's product class one products concerns could implicate entire class turn could adverse impact availability commercial viability products well products class illegal distribution sale third parties counterfeit unregistered versions products stolen products could negative impact revenues earnings reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug product diverted authorized market may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name diverted products prevalence counterfeit medicines industrywide issue due variety factors including adoption ecommerce increased covid pandemic greatly enhancing consumers ability obtain prescriptions medical treatments via internet lieu traditional brick mortar pharmacies internet exposes patients greater risk preferred vehicle dangerous counterfeit offers scams anonymity affords counterfeiters thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business addition diversion products authorized market channels may result reduced revenues negatively affect profitability increased use social media platforms presents risks challenges increasing use social media communicate company news events inappropriate andor unauthorized use social media could cause brand damage information leakage may give rise liability including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill may cause significant volatility stock price disclosure nonpublic companysensitive information workforce others whether intentional unintentional external media channels could lead loss trade secrets intellectual property well companys commercially sensitive information information technology cybersecurity risks dependent information technology systems face risk cybersecurity incidents could disrupt business result theft proprietary confidential information rely extensively information technology systems networks services including internet sites data hosting processing facilities tools physical security systems hardware software technical applications platforms managed hosted provided andor used third parties vendors assist conducting business faced continue face risks incidents whether cyber attacks cyber intrusions cloud internet phishing attempts ransomware forms malware computer viruses email attachments extortion scams although make efforts maintain security integrity information technology systems systems proprietary confidential personal information resides transmitted subject risk cybersecurity incident disruption assurance security efforts measures thirdparty vendors prevent breakdowns incidents thirdparty vendors systems could adversely affect business strategy results operations financial condition cybersecurity risks continue develop including result threat actors increasingly targeting employees supply chains geopolitical tensions leading increase sabotage espionage cyber attacks cyberthreat landscape evolves attacks growing frequency sophistication intensity due nature attacks also risk may remain undetected period time significant breakdown invasion corruption destruction interruption critical information technology systems leak theft proprietary confidential personal information could negatively impact operations assurance continuing efforts prevent breakdowns incidents thirdparty providers systems databases could adversely affect business certain circumstances incidents detected could require disclosure government authorities andor regulators could require notification impacted individuals incident could result material financial legal business reputational harm us strategic business development employee attraction retention risks depend several key products revenues cash flows earnings derive majority revenue earnings several key products expect revlimid eliquis opdivo represent significant percentage revenue earnings cash flows next years reduction revenue products due loss market exclusivity factors could adversely impact earnings cash flows additional information see item risk factorswe could lose market exclusivity product earlier expected also one major products become subject issues loss patent protection significant changes demand formulary access changes material product liability unexpected side effects regulatory proceedings negative publicity supply disruption manufacturing operations third party supplier significant advancement competing products may incur adverse impact business financial condition results operations trading price stock addition us products distributed wholesalers one wholesalers encounter financial difficulties might unable timely collect amounts wholesaler owes us could negatively impact results operations thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent significant percentage pretax income including royalties related divestiture diabetes business including transfer certain future royalty rights pertaining amylin onglyza farxiga product sales outlicensed intellectual property merck patent infringement settlement pretax income generated royalties approximately billion pretax income could adversely affected royalty streams decline future periods example royalties related keytruda decreased january expected terminate december royalties related tecentriq expected terminate december addition royalties divested diabetes business specifically amylin farxiga onglyza terminate december failure execute business strategy identify effectively manage acquisitions divestitures alliances joint ventures portfolio actions could adversely impact growth profitability future results addition businesses assets acquire future may underperform may able successfully integrate existing business occurrence number unexpected factors could prevent substantially delay consummation anticipated acquisition divestiture merger strategy focused delivering innovative transformational medicines patients focused set disease areas support future revenue growth maintain adequate pipeline acquired inlicensed number assets expect continue support pipeline compounds products obtained licensing acquisitions competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions unable consistently maintain adequate pipeline whether internal rd programs transactions third parties unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change operating model evolution manage costs effectively operating results financial condition could negatively impacted additionally future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due low product uptake delayed missed pipeline opportunities inability capture expected synergies resulting cost savings avoidance increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii tax considerations acquire debt equity securities part consideration business development activities connection joint venture acquisition value securities fluctuate may depreciate value may control company acquire securities connection collaborative arrangement result limited ability determine management operational decisions internal controls compliance policies result additional financial reputational risks may successful separating underperforming nonstrategic assets gains losses divestiture lost operating income assets may affect earnings divestitures also may result continued financial exposure divested businesses guarantees financial arrangements continued supply services arrangements potential litigation following transaction arrangements nonperformance us could result obligations imposed us could material adverse effect competitive position cash flows results operations financial condition reputation might also incur asset impairment charges related acquisitions divestitures reduce earnings value allocated certain assets could substantially impaired due number factors beyond control new revised accounting standards rules interpretations could result changes recognition income expense may materially adversely affect financial results execution implementation acquisitions divestitures alliances joint ventures portfolio actions successful could adversely impact financial condition cash flows results operations moreover due substantial amount debt incurred finance cash portion celgene myokardia mirati acquisitions intend incur connection karuna rayzebio acquisitions assurance able expand business development capacity although committed reducing debt pursuing strategic transaction opportunities future may require us obtain additional equity debt financing could result increased leverage andor downgrade credit ratings failure attract retain highly qualified workforce could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management workforce including people expertise clinical rd governmental regulation commercialization ii connection acquisitions integrate corporate cultures maintain employee morale facing increasing competition limited pool qualified individuals numerous pharmaceutical biotechnology companies universities government entities research institutions companies seeking enter healthcare space companies industries sure able retain quality talent costs materially increase market liquidity credit risks significant indebtedness could negative consequences acquisitions celgene myokardia mirati increased amount debt resulting additional interest expense intend incur debt finance future acquisitions including karuna rayzebio acquisitions could reduce financial flexibility continue capital investments develop new products declare future dividends example following announcements recent acquisitions standard poors downgraded bmss long termcredit rating stable longterm credit outlook adverse changes us global economic political conditions could adversely affect operations profitability global economic political risks pose significant challenges companys growth profitability difficult mitigate generated approximately revenues outside us global economic downturn could create amplify variety risks business could negatively affect growth addition uncertainty credit capital markets could impact growth strategy revenues earnings cash flow also exposed risk strengthening us dollar global inflation including us operating costs significantly increase whether result rising inflation rates wage increases factors could adversely affect revenues profitability also exposure customer credit risks europe south america markets including governmentguaranteed hospital receivables markets payments received time significant operations europe including manufacturing distribution results operations could negatively impacted member country exiting eurozone monetary union eu particular exit uk eu occurred january created uncertainties affecting business operations uk eu may impact research commercial general business operations uk eu including approval supply products may require changes legal entity structure uk eu additionally business operations may adversely affected political volatility conflicts crises individual countries regions including terrorist activities war pandemics epidemics covid pandemic affected demand products driven lower patient starts visits would expect future pandemics similar effect addition experience significant manufacturing supply issues due covid possible could experience issues response future pandemics instance may experience scarcity certain raw materials components result influx pandemic related vaccine orders receiving priority treatment vendors furthermore future epidemic pandemic could create material staffing shortages manufacturing sites could disrupt supply products also possible may experience supply chain interruptions result quarantines shelterinplace governmental orders policies travel restrictions airline cargo capacity route reductions may also experience delays initiation enrollment patients clinical trials consequence future pandemic may able fully mitigate delays could negatively impact timing pipeline development programs expected future revenues andor cash flows prolonged clinical trial delay could potentially significant negative effect business particularly new competitive products enter market clinical trial results competitors products affect value proposition product delays difficulties clinical development could also potentially lead material impairment intangible assets including billion intangible assets december predict reasonably estimate impact potential longterm changes healthcare industry global economic political events including future pandemics example potential shift us payer channel mix due changes patient coverage current economic crisis able reliably estimate impact would results operations given highly variable uncertain situation also possible changes healthcare system could impose additional burdens clinical trials could increase costs sponsoring clinical trials lead additional delays difficulties completing clinical trials may also experience additional pricing pressures andor increased governmental regulation global economic conditions events wars pandemics also create additional risks impact suppliers vendors outsourcing partners alliance partners third parties rely research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance business unit functional services example thirdparty providers suffer limited solvency global economic conditions could negatively impact operating model business similarly global events ukraine russia conflict increase volatility financial markets foreign currency exchanges interest rates could also face potential negative consequences stemming future pandemics global events including limited increased cyber threats us partners cyber attacks outages possible global economic political events including future pandemic could exacerbate risks described well guarantee pay dividends repurchase stock declaration amount timing dividends fall within discretion board boards decision depend many factors including financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board may deem relevant reduction elimination dividend payments dividend program could adversely affect stock price addition could time decide buy back shares market reduce number shares repurchased share repurchase program could also adversely affect stock price ira imposes excise tax net repurchases shares december imposition excise tax repurchases shares may increase cost us making repurchases may cause board reduce number shares repurchased pursuant share repurchase program amended bylaws designate court chancery state delaware sole exclusive forum certain lawsuits us stockholders could limit stockholders ability obtain judicial forum finds favorable lawsuits make costly stockholders bring lawsuits may effect discouraging lawsuits amended bylaws provide unless consent writing selection alternative forum court chancery state delaware fullest extent permitted law sole exclusive forum derivative action proceeding brought behalf ii action asserting claim breach fiduciary duty owed directors officers employees us stockholders creditors constituents iii action asserting claim arising pursuant provision general corporation law state delaware amended restated certificate incorporation amended bylaws iv action asserting claim us directors officers employees governed internal affairs doctrine provided however event court chancery state delaware lacks jurisdiction action proceeding sole exclusive forum action proceeding another state federal court state delaware bylaws also provide person entity purchasing otherwise acquiring holding interest shares capital stock deemed notice consented forum selection provision court chancery state delaware court chancery jurisdiction another state federal court state delaware fullest authority allowed law issue antisuit injunction enforce forum selection clause preclude suit forum however forum selection provision intended apply actions brought securities act securities act amended exchange act section exchange act creates exclusive federal jurisdiction suits brought enforce duty liability created exchange act rules regulations thereunder section securities act creates concurrent jurisdiction federal state courts suits brought enforce duty liability created securities act rules regulations thereunder accordingly forum selection provision amended bylaws relieve us duties comply federal securities laws rules regulations thereunder stockholders deemed waived compliance laws rules regulations nevertheless forum selection provision bylaws may limit stockholders ability bring claim judicial forum finds favorable disputes us directors officers employees may discourage lawsuits respect claims although stockholders deemed waived compliance federal securities laws rules regulations thereunder addition stockholders bring claim court chancery state delaware could face additional litigation costs pursuing claim particularly reside near delaware believe risk court declining enforce forum selection provision contained amended bylaws low court find provision inapplicable unenforceable respect one specified types actions proceedings may incur additional costs associated resolving action jurisdictions could harm business operating results financial condition item b unresolved staff comments none item c cybersecurity risk management strategy company manages cybersecurity risk part overall enterprise risk management strategy overseen audit committee board company employs robust cybersecurity data privacy programs largely aligned among others us national institute standards technology cybersecurity framework assess identify manage material risks cybersecurity threats constantly evolving cyber defenses minimize impacts cyber threats using multipronged approach helps safeguard assets data particularly focused addressing emerging cybersecurity risks including human risk phishing attacks remain one common causes data breaches thirdparty supply chain risks threat actors continue target supply chains compromise greater number victims geopolitical risk tensions conflicts around world often accompanied increase sabotage espionage cyber attacks threat actors frequently target employees gain access information systems comprehensive global human risk management program educates workforce threats face first line defense includes elements addressing phishing malware data handling device security cybersecurity education password security internet browsing defenses physical threats employees exposed datadriven cybersecurity awareness campaigns training order keep pace industry standards evolving challenges innovative solutions respect information security data privacy cybersecurity risks organization additionally employ multilayered approach application cybersecurity technologies help safeguard systems networks data potential cybersecurity threats companies acquire integration plans include appropriate workable timelines alignment information security data privacy cybersecurity employee education support preparedness cybersecurity incident response plan cirp regularly update business needs security landscapes change event cybersecurity incident incident response team refers cirp existing management internal controls disclosure processes pursuant process designated personnel responsible assessing severity incident associated threats containing resolving incident quickly possible managing damage companys systems networks minimizing impact companys stakeholders analyzing executing upon internal reporting obligations escalating information incident senior management appropriate performing postincident analysis program enhancements needed perform periodic tabletop exercises annually test incident response procedures identify gaps improvement opportunities exercise team preparedness engage third parties separately conduct cyber assessments recurring basis assist containment remediation efforts addition third party technology analytics utilized identify potential vulnerabilities recognize third parties provide services company subject cybersecurity incidents could impact company manage thirdparty risk maintain thirdparty risk management program designed assess security controls third parties assessment methodology based risk relies data access connectivity criticality services thirdparty offers noted also conduct tabletop exercises identify gaps supply chain resilience implement improvements maintain relationships law enforcement government agencies forensic investigators legal counsel inform cybersecurity data privacy programs december date filing aware material cybersecurity incidents impacted company however target cyber attacks expect continue cybersecurity threats rapidly evolving sophistication becoming prevalent industry face risks incidents whether cyber attacks cyber intrusions cloud internet phishing attempts ransomware forms malware computer viruses email attachments extortion scams although make efforts maintain security integrity information technology systems systems proprietary confidential personal information resides transmitted subject risk cybersecurity incident disruption assurance security efforts measures third party vendors prevent breakdowns incidents thirdparty vendors systems could adversely affect business discussion risks see item arisk factorsinformation technology cybersecurity riskswe dependent information technology systems infrastructure face certain risks including cybersecurity incidents data leakage governance companys cybersecurity data privacy programs implemented overseen companys chief information security officer ciso executive vice president chief digital technology officer senior management information security team responsible managing implementing companys cybersecurity data privacy programs many years valuable business experience managing risks cybersecurity threats data privacy breaches developing implementing cybersecurity data privacy policies procedures audit committee consists solely independent directors oversees companys overall enterprise risk assessment risk management policies guidelines including risks related cybersecurity matters audit committee reviews discusses management oversees companys information security data protection programs particular audit committee receives periodic updates ciso internal audit function members management significant cybersecurity data privacy threats systems potential impact companys business financial results operations reputation risk management strategies including information governance security policies programs program assessments planned improvements major legislative regulatory developments could materially impact companys cybersecurity data privacy policies programs status information security initiatives including appropriate threat assessment relating information technology risks update chair audit committee updates full board board also receives similar cybersecurity updates directly ciso members management least annually needed time time item properties principal executive offices located route province line road princeton nj lease manufacturing rd administration storage distribution facilities approximately sites worldwide believe manufacturing properties combination thirdparty manufacturers good operating condition provide adequate production capacity current projected operations also believe none properties subject material encumbrance easement restriction would detract materially value impair use operation business information manufacturing properties refer item businessmanufacturing quality assurance significant manufacturing rd locations geographic area follows december manufacturing rd united states europe total item legal proceedings information pertaining legal proceedings found item financial statements supplementary datanote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia information executive officers listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting shareholders thereafter elected oneyear term successors elected executive officers serve discretion board directors name current position age employment history past years president head us commercial christopher boerner phd president head international markets chief executive officer executive vice president chief commercialization officer member leadership team executive vice president chief operating officer present chief executive officer giovanni caforio md chief executive officer director company executive chairman board chairman board chief executive officer member leadership team present executive chairman board group vice president chief financial officer consumer consumer medicines johnson johnson david v elkins worldwide vice president chief financial officer consumer products medical executive vice president chief financial officer development corporate functions johnson johnson member leadership team chief financial officer celgene corporation present executive vice president chief financial officer cari gallman senior counsel us legal executive vice president corporate affairs assistant general counsel oncology legal member leadership team vice president assistant general counsel worldwide oncology senior vice president chief compliance officer present executive vice president corporate affairs vice president investor relations abbvie inc head pricing us commercial abbvie inc sharon greenlees head supply chain finance abbvie inc senior vice president corporate controller vice president controller rd finance operations abbvie inc present senior vice president corporate controller samit hirawat md executive vice president head oncology development novartis executive vice president chief medical officer head development executive vice president chief medical officer global drug development member leadership team present executive vice president chief medical officer head development vice president immunooncology marketing lynelle hoch general manager ireland uk major markets president cell therapy organization senior vice president global cell therapy franchise lead member leadership team present president cell therapy organization head us oncology adam lenkowsky senior vice president general manager us oncology immunology cardiovascular executive vice president chief commercialization officer senior vice president head major markets member leadership team present executive vice president chief commercialization officer sandra leung executive vice president general counsel present executive vice president general counsel member leadership team greg meyers corporate vice president chief information officer motorola solutions executive vice president chief digital technology officer group chief information digital officer syngenta group member leadership team present executive vice president chief digital technology officer vice president inflammation immunology thematic center excellence unit robert plenge md phd celgene corporation executive vice president chief research officer head research senior vice president immunology cardiovascular fibrosis thematic research center member leadership team senior vice president immunology cardiovascular fibrosis thematic research center head translational medicine senior vice president head discovery translational sciences present executive vice president chief research officer head research amanda poole vice president head human resources global product development supply executive vice president chief human resources officer vice president head bmscelgene integration member leadership team senior vice president head human resources commercialization senior vice president people strategy solutions services present executive vice president chief human resources officer karin shanahan senior vice president chief operating officer global operations teva pharmaceuticals executive vice president global product development supply senior vice president global biologics sterile operations merck member leadership team present executive vice president global product development supply part ii item market registrants common equity related stockholder matters issuer purchases equity securities bristol myers squibb common stock traded new york stock exchange symbol bmy holders common stock number record holders common stock january number record holders based upon actual number holders registered books date based information provided eq shareowner services transfer agent include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies equity compensation plan information information required item contained proxy statement heading items voted uponitem advisory vote approve compensation named executive officersequity compensation plan information information incorporated herein reference performance graph following graph compares cumulative total stockholders returns common shares cumulative total stockholders returns companies listed standard poors index sp index composite peer group major pharmaceutical companies comprised abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assumes investment december common shares sp index stock peer group companies including reinvestment dividends years ended december stock price performance following graph necessarily indicative future stock price performance bristol myers squibb sp peer group issuer purchases equity securities following table summarizes surrenders equity securities three months ended december total number shares approximate dollar value purchased part shares may yet total number average price paid per publicly announced purchased period shares purchaseda sharea programsb programsb dollars millions except per share data october november c december three months ended december includes shares repurchased part publicly announced programs shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock following authorization board subsequently approved additional authorizations including recently february january december december amount billion billion billion billion respectively share repurchase authorization remaining share repurchase capacity program billion december refer item financial statements supplementary datanote equity information share repurchase program c represents approximately million shares asr settled transferred treasury stock completed repurchases pursuant asr average repurchase price refer item financial statements supplementary datanote equity information item reserved item managements discussion analysis financial condition results operations managements discussion analysis financial condition results operations provided supplement read conjunction consolidated financial statements related notes included elsewhere enhance understanding results operations financial condition cash flows comparison results omitted incorporated reference year ended december item managements discussion analysis financial condition results operations filed february executive summary bristolmyers squibb company global biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end definitions capitalized terms used throughout document received approvals initial additional indications following marketed products major markets us eu japan expanded geographical reach immunology hematology oncology cardiovascular diseases us eu approval opdivo treatment completely resected stage iib iic melanoma expanding upon existing adjuvant treatment melanoma patients ii fda approval reblozyl firstline setting treatment anemia without previous erythropoiesis stimulating agent use adult patients low intermediaterisk mds may also require red blood cell transfusions regardless ring sideroblast status eu approval additional indication anemia associated nontransfusiondependent beta thalassemia iii approvals japan eu opdivo combination chemotherapy neoadjuvant treatment patients resectable nsclc iv approval camzyos treatment symptomatic obstructive hcm eu v approval breyanzi secondline treatment diffuse large bcell lymphoma eu vi approval sotyktu moderatetosevere plaque psoriasis eu vii approval augtyro repotrectinib next generation tyrosine kinase inhibitor tki treatment adult patients locally advanced metastatic ros nonsmall cell lung cancer nsclc us continue expanding commercial cart manufacturing network fda approval devens facility june january acquired mirati commercial stage targeted oncology company pipeline commercial clinical preclinical stage oncology medicines assets mirati acquisition obtained rights krazati bestinclass inhibitor krasgc mutation approved fda secondline treatment patients nsclc mrtx potential firstinclass mtacooperative prmt inhibitor phase development among others addition fourth quarter entered definitive merger agreements acquire karuna rayzebio also entered strategic collaboration systimmune karuna biopharmaceutical company driven discover develop deliver transformative medicines people living psychiatric neurological conditions rayzebio clinicalstage radiopharmaceutical therapeutics company innovationleading position actiniumbased radiopharmaceutical therapeutics pipeline potentially firstinclass bestinclass drug development programs refer item financial statements supplementary datanote acquisitions divestitures licensing arrangements additional information goal collaboration systimmune codevelop cocommercialize blbd bispecific topoisomerase inhibitorbased antibody drug conjugate targets egfr currently evaluated phase clinical trial metastatic unresectable nsclc refer item financial statements supplementary data note alliances information company potential increase registrational portfolio six twelve potentially firstinclassbestinclass assets addition growing registrational portfolio company indication expansion opportunities horizon taken together leads increased depth across companys therapeutic areas including oncology hematology immunology cardiovascular growing presence neuroscience financial highlights year ended december dollars millions except per share data total revenues diluted earnings per share gaap nongaap revenues decreased primarily due lower revlimid sales driven previously disclosed generic erosion increase patients receiving free drug product revlimid lesser extent pomalyst bristol myers squibb patient assistance foundation partially offset higher sales new product portfolio inline products primarily opdivo increase gaap eps primarily driven impact certain specified items including deferred income tax benefit related nonus tax ruling lower losses equity investments amortization intangible assets well litigation settlement income partially offset lower revenues product mix adjusting specified items nongaap eps decreased primarily result lower revenues product mix partially offset higher royalty interest income lower weighted average shares outstanding nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations changes nongaap financial measures refer nongaap financial measures economic market factors governmental actions products continue subject increasing pressures across portfolio pharmaceutical market access pricing controls discounting changes tax importation laws restrictions us eu regions around world result lower prices lower reimbursement rates smaller populations payers reimburse negatively impact results operations including intangible asset impairment charges operating cash flow liquidity financial flexibility example august president biden signed ira law provides government negotiate prices select highcost medicare part beginning part b drugs beginning nine years smallmolecule drugs years biological products fda approval ii manufacturers pay rebate medicare part b part drugs prices increase faster inflation beginning part part b iii medicare part redesign replaces current part cgdp establishes cap outofpocket limits costs medicare beneficiaries beginning manufacturers responsible costs cap cap reached august us department health human services selected eliquis one first medicines subject governmentset prices beginning possible products could selected future years could among things accelerate revenue erosion prior expiry intellectual property protections addition december biden administration released proposed framework first time proposed drugs price factor determining drug accessible public therefore government could exercise marchin rights license third party manufacture comment period proposal ran february able predict whether final rule adopted along lines proposed adopted whether government would seek exercise marchin rights products proposals relating calculation best price well potential executive orders focused drug pricing still debated effect reducing prices reimbursement certain products would significantly impact business consolidated results operations additionally connection ira following changes made us tax laws including minimum tax generally applies us corporations adjusted financial statement income beginning ii nondeductible excise tax provision net stock repurchases applied repurchases beginning continue evaluate impact ira legislation results operations possible changes may result material impact business results operations furthermore countries expected make changes tax laws updates international tax treaties implement agreement oecd establish global minimum tax see risk factors items included part iitem risk factorsproduct industry operational risksincreased pricing pressure restrictions us abroad continue negatively affect revenues profit margins could lose market exclusivity product earlier expected changes tax regulations could negatively impact earnings significant product approvals following summary significant approvals received product date approval augtyro fda approval augtyro treatment adult patients locally advanced metastatic ros november repotrectinib positive nsclc fda approval opdivo adjuvant treatment adult pediatric patients years older opdivo october completely resected stage iib iic melanoma fda approval reblozyl treatment anemia without previous erythropoiesis stimulating agent reblozyl august use esanave adult patients low intermediaterisk mds ec approval opdivo monotherapy adjuvant treatment adults adolescents years opdivo august age older stage iib iic melanoma undergone complete resection ec approval opdivo combination platinumbased chemotherapy neoadjuvant treatment opdivo june resectable nsclc high risk recurrence adult patients tumor cell pdl expression ec approval camzyos treatment symptomatic new york heart association class iiiii camzyos june obstructive hcm ec approval breyanzi treatment adult patients diffuse large bcell lymphoma high grade b breyanzi may cell lymphoma primary mediastinal large bcell lymphoma fl grade b relapsed within months completion refractory firstline chemoimmunotherapy japan 's ministry health labour welfare approval opdivo plus chemotherapy neoadjuvant opdivo march treatment patients resectable nsclc ec approval sotyktu treatment adults moderatetosevere plaque psoriasis sotyktu march candidates systemic therapy ec approval reblozyl treatment adult patients anemia associated nontransfusion reblozyl march dependent beta thalassemia refer product pipeline developments developments marketed products latestage pipeline early strategy principal strategy combine resources scale capability large pharmaceutical company speed agility focus innovation typically found biotech industry priorities continue renew diversify portfolio launching new medicines ii advancing early mid latestage pipeline iii executing disciplined business development undergo period renewal strategy focused driving nearterm growth minimizing impact transition period follows delivering growth late accelerating opportunities enhance productivity efficiency advance pipeline drive strong commercial execution move business forward remain committed strategic business development maintaining strong investment grade credit rating growing dividend reducing additional debt issued support recent transactions focus discovering developing delivering transformational medicines patients facing serious diseases following five core therapeutic areas oncology priority certain tumor types including diversification beyond io ii hematology opportunities expand leadership position multiple myeloma well broaden portfolio across leukemias lymphomas nonmalignant hematologic diseases iii immunology priorities strengthening presence dermatology rheumatology gastrointestinal disorders establishing new standards care pulmonology rapidly advance cell therapy immunology diseases iv cardiovascular diseases focus cardiomyopathies heart failures thrombotic diseases v neuroscience focus neuropsychiatry neurodegenerative neuroinflammation diseases working towards expanding pipeline registrational assets six twelve addition positioned support continued innovation expand treatment options across several different diseases based differentiated research platforms broad portfolio pipeline comes autologous cart cell therapies two approved cell therapies two distinct targets continuing build leadership space expanding manufacturing capacity exploring innovative technologies dualtargeting carts allogenic approaches advancing multiple nextgeneration assets including new targets rapidly expanding immunology including lupus multiple sclerosis also strong position protein degradation field advancing pipeline expansive library assets two registrational trials additional five clinical phase studies fifteen studied preclinically growing platform potential across several diseases positioned deliver approximately four inds year together proven track record rapidly advancing pipeline growth marketed products increased sustained rd productivity enabling us identify highquality candidates increase probability reaching patients need specifically ambition deliver approximately ten inds per year ii increase success rates firstinhuman trials approval approximately iii reduce timelines achieve median years firstinhuman trials approval rd strategy help ensure maintain strong legacy scientific innovation bringing firstin class andor bestinclass treatments patients accelerated speed commercial model successful revenues inline brands new product portfolio continuing grow demonstrates strong execution strategy remain focused wellresourced cancer development programs seek broaden use opdivo earlier lines therapy expand new tumors accelerate next wave oncology mechanisms develop treatment options refractory oncology patients encouraged investigational subcutaneous formulation opdivo potential bring enhanced benefits patients next decade positive registrational data inhouse continue drive adoption opdivo expanding additional indications tumor types monotherapy combination yervoy anticancer agents strengthening io portfolio opdualag treatment melanoma potential expanded opportunities indications growing differentiated nsclc portfolio includes launch augtyro includes krazati acquired mirati demonstrates strategic fit oncology portfolio also strengthening neuroscience portfolio planned acquisition karuna moreover eliquis continues grow leveraging best class clinical profile extensive real world data remains number one novel oral anticoagulant total prescriptions globally camzyos continues demonstrate benefits shared longterm followup data two phase iii studies immunology sotyktu key growth driver bms continue make investments accelerate launch direct consumer advertising adding field force support addition phase iii registrational clinical trials underway sotyktu psa sle sjgren 's syndrome able leverage leading capabilities hematological malignancies robust pipeline provide opportunities longterm growth offset impact current future patent expiries revlimid pomalyst look cell therapy franchise continue explore new indications breyanzi include treatment cll fl mcl indication cll approved would first cart available patient population reblozyl advancing new indications ongoing registrational trial chronic anemia associated myelofibrosis evolution operating model focuses maintaining disciplined approach marketing selling administrative expenses enable us deliver necessary strategic financial operational flexibility invest highest priority opportunities within portfolio strategy extends well beyond discovery development delivery transformative medicines help patients prevail serious diseases understand future employees communities planet business inextricably linked environmental social governance esg strategy seek mobilize capabilities resources positively impact communities live work serve around world work transform patients lives science operate effective governance uncompromising quality compliance highest ethical standards deliver mission values central since company founded believe driving longterm business value heart living purpose enabling us leaders differencemakers generations come acquisitions divestitures licensing arrangements detailed information significant acquisitions divestitures collaborations licensing arrangements refer item financial statements supplementary data note alliances note acquisitions divestitures licensing arrangements results operations regional revenues composition changes revenues follows year ended december dollars millions change foreign exchangeb united states na international othera na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period revenues united states us revenues decreased primarily due lower revlimid sales driven previously disclosed generic erosion increase patients receiving free drug product revlimid lesser extent pomalyst bristol myers squibb patient assistance foundation separate independent c entity bms donates product partially offset increase demand inline products new product portfolio average net selling prices remained flat compared international international revenues decreased primarily due revlimid eliquis generic erosion lower average net selling prices foreign exchange impacts partially offset increase demand opdivo new product portfolio single country outside us contributed total revenues business typically seasonal gtn adjustments recognize revenue net gtn adjustments described critical accounting policies activities ending reserve balances significant category gtn adjustments follows rebates chargebacks medicaid returns discounts dollars millions cash discounts medicare rebates adjustments total balance january provision related sales made current period prior period payments returns foreign currency translation balance december reconciliation gross product sales net product sales significant category gtn adjustments follows year ended december change dollars millions vs gross product sales gtn adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales gtn adjustments percentage us nonus reductions provisions product sales made prior periods resulting changes estimates million million respectively reductions provisions driven nonus revisions clawback amounts driven vat recoverable estimates gtn adjustments primarily function product sales volume regional payer channel mix contractual legislative discounts rebates us gtn adjustments percentage increased primarily due higher government channel mix higher gtn adjustment percentages nonus gtn adjustments percentage increased primarily due continued pricing pressures product revenues year ended december dollars millions change inline products eliquis us nonus opdivo us nonus orencia us nonus pomalystimnovid us nonus yervoy us nonus sprycel us nonus mature products us nonus total inline products us nonus year ended december dollars millions change new product portfolio reblozyl us nonus opdualag us nonus na abecma us nonus zeposia us nonus breyanzi us nonus camzyos us nonus na sotyktu us nonus na onureg us nonus inrebic us nonus augtyro na us na nonus na total new product portfolio us nonus total inline products new product portfolio us nonus year ended december dollars millions change recent loe productsa revlimid us nonus abraxane us nonus total recent loe products us nonus total revenues us nonus change excess recent loe products include products significant expected decline revenue prior reporting period result loe eliquis apixaban oral factor xa inhibitor indicated reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence following initial therapy us revenues increased primarily due higher demand international revenues decreased primarily due lower average net selling prices generic erosion uk canada excluding foreign exchange impacts revenues decreased following may expiration regulatory exclusivity eliquis europe court decision uk finding uk apixaban compositionof matter patent related spc invalid generic manufacturers begun marketing generic versions eliquis uk portugal may seek market generic versions eliquis additional countries europe prior expiration patents led additional infringement invalidity actions involving eliquis patents filed various countries europe recently france norway sweden courts held bms 's favor confirming validity composition matter patent related spcs countries believe innovative science behind eliquis strength intellectual property defend infringement refer item financial statementsnote legal proceedings contingenciesintellectual property information opdivo nivolumab fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen also approved multiple markets treatment nsclc melanoma mpm rcc crc various gastric esophageal cancers several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents us revenues increased due higher demand across multiple indications lesser extent higher average net selling prices higher demand related following indications opdivoyervoy combinations nsclc various gastric esophageal bladder cancers international revenues increased primarily due higher demand result core indications additional indication launches partially offset foreign exchange impact excluding foreign exchange impacts revenues increased orencia abatacept fusion protein indicated adult patients moderate severe active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate us revenues increased primarily due higher demand international revenues increased due higher demand partially offset foreign exchange impact excluding foreign exchange impacts revenues increased bms aware orencia biosimilars market us eu japan formulation additional patents expire beyond pomalystimnovid pomalidomide proprietary distinct small molecule administered orally modulates immune system biologically important targets pomalystimnovid indicated patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor demonstrated disease progression within days completion last therapy us revenues decreased due increase number patients receiving free drug product bristol myers squibb patient assistance foundation separate independent c entity bms donates products partially offset higher average net selling prices international revenues increased due higher demand partially offset lower average net selling prices foreign exchange impacts excluding foreign exchange impacts revenues increased eu estimated minimum market exclusivity date august yervoy ipilimumab ctla immune checkpoint inhibitor yervoy monoclonal antibody treatment patients unresectable metastatic melanoma opdivoyervoy regimen approved multiple markets treatment nsclc melanoma mpm rcc crc esophageal cancer us revenues increased due higher average net selling prices demand international revenues increased due higher demand result additional indication launches core indications partially offset lower average net selling prices foreign exchange impacts excluding foreign exchange impacts revenues increased sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment patients philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate treatment children adolescents aged year years chronic phase philadelphia chromosomepositive cml us revenues decreased due lower average net selling prices driven unfavorable gtn adjustments international revenues decreased due lower demand result generic erosion lower average net selling price foreign exchange impact excluding foreign exchange impact revenues decreased us bms entered settlement agreements certain third parties sell generic dasatinib products beginning september earlier certain circumstances eu generic dasatinib products entered market japan composition matter patent extended treatment nonimatinibresistant cml generics approved indications mature products includes products including lost exclusivity major markets otc products royalty revenue mature products international revenues mature products decreased primarily due lower demand result continued generic erosion foreign exchange impacts excluding foreign exchange impacts revenues decreased reblozyl luspaterceptaamt erythroid maturation agent indicated treatment anemia adult patients transfusion dependent non transfusion dependent beta thalassemia require regular red blood cell transfusions ii adult patients low intermediaterisk mds ring sideroblasts require red blood cell transfusions well iii adult patients without previous erythropoiesis stimulating agent use esanave low intermediaterisk mds may require regular red blood cell transfusions regardless ring sideroblast status us revenues increased primarily due higher demand opdualag nivolumab relatlimabrmbw combination nivolumab pd blocking antibody relatlimab lag blocking antibody indicated treatment adult pediatric patients years age older unresectable metastatic melanoma opdualag launched march abecma idecabtagene vicleucel bcma genetically modified autologous cart cell therapy indicated treatment adult patients relapsed refractory multiple myeloma four prior lines therapy including immunomodulatory agent proteasome inhibitor anticyclic adp ribose hydrolase monoclonal antibody us revenues increased primarily due higher demand enabled additional manufacturing capacity zeposia ozanimod oral immunomodulatory drug used treat relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease adults treat moderately severely active uc adults us revenues increased primarily due higher demand breyanzi lisocabtagene maraleucel cddirected genetically modified autologous cart cell therapy indicated treatment adult patients relapsed refractory large bcell lymphoma one lines systemic therapy including diffuse large bcell lymphoma otherwise specified highgrade bcell lymphoma primary mediastinal large bcell lymphoma fl grade b us revenues doubled sales primarily due higher demand camzyos mavacamten cardiac myosin inhibitor indicated treatment adults symptomatic obstructive hcm improve functional capacity symptoms camzyos launched april sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicated treatment adults moderatetosevere plaque psoriasis candidates systemic therapy phototherapy sotyktu launched september onureg azacitidine oral hypomethylating agent incorporates dna rna indicated continued treatment adult patients aml achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy us revenues increased primarily due higher demand inrebic fedratinib oral kinase inhibitor indicated treatment adult patients intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia mf us revenues increased primarily due higher demand augtyro repotrectinib kinase inhibitor indicated treatment adult patients locally advanced metastatic rospositive nsclc augtyro launched december revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicated treatment patients multiple myeloma revlimid single agent also indicated maintenance therapy patients multiple myeloma following autologous hematopoietic stem cell transplant revlimid received approvals several indications hematological malignancies including lymphoma mds us revenues decreased primarily due generic erosion increase number patients receiving free drug product bristol myers squibb patient assistance foundation separate independent c entity bms donates products lesser extent lower average net selling prices international revenues decreased primarily due generic erosion across several european countries foreign exchange impacts excluding foreign exchange impacts revenues decreased us certain third parties granted volumelimited licenses sell generic lenalidomide beginning march thereafter pursuant licenses several generics entered expected enter us market volumelimited quantities generic lenalidomide eu japan generic lenalidomide products entered market global revenues revlimid expected decline range approximately billion billion abraxane paclitaxel albuminbound particles injectable suspension solventfree proteinbound chemotherapy product combines paclitaxel albumin using proprietary nab technology platform used treat breast cancer nsclc pancreatic cancer among others us revenues increased primarily due higher branded sales resulting lower authorized generic sales estimated enduser demand pursuant sec consent order described sec consent order monitor inventory levels hand us wholesaler distribution channel outside us direct customer distribution channel disclose products levels inventory excess one month hand expected demand subject certain limited exceptions none december us distribution channels september nonus distribution channels us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products year ended december factors may influence estimates include generic erosion seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes camzyos available restricted program called camzyos rems program product distribution limited rems certified pharmacies enrolled pharmacies must dispense patients authorized receive camzyos revlimid pomalyst distributed us primarily contracted pharmacies lenalidomide rems pomalyst rems programs respectively proprietary riskmanagement distribution programs tailored specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distributed mandatory riskmanagement distribution programs tailored meet local authorities specifications provide products safe appropriate distribution use programs may vary country depending upon country design riskmanagement program product may sold hospitals retail pharmacies nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers thirdparty market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing disclose product levels inventory excess one month hand expected demand current quarter subject certain limited exceptions next quarterly report form q expenses year ended december dollar millions change cost products sold marketing selling administrative research development acquired iprd amortization acquired intangible assets incomeexpense net total expenses change excess excludes amortization acquired intangible assets cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty product supply costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing foreign currency hedge settlement gains losses impairment charges well proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs cost products sold excludes amortization acquired intangible assets cost products sold increased million primarily due higher inventory costs million driven product mix cart cell therapy costs higher royalties profit sharing million lower hedging settlement gains million partially offset elimination puerto rico excise tax million lower inventory purchase price adjustments million marketing selling administrative marketing selling administrative expenses primarily include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion costs well proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements marketing selling administrative expenses decreased million primarily due timing charitable giving million cash settlement turning point unvested stock awards million partially offset higher advertising promotion costs resulting additional new product launches million site exit costs million research development research development activities include research early discovery preclinical clinical development drug formulation medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements research development expense decreased million primarily due costs related unwinding inventory purchase price adjustments clinical use million cash settlement turning point unvested stock awards million partially offset purchase priority review voucher million acquired iprd acquired iprd expenses comprised upfront payments contingent milestone payments connection asset acquisitions inlicense arrangements thirdparty intellectual property rights well upfront contingent milestones payable bms alliance partners prior regulatory approval acquired iprd charges detailed table year ended december dollars millions mavacamten rights buyout note orum upfront payment note mavacamten royalty extinguishment note dragonfly milestone optin license fee evotec designation optin license fees bridgebio upfront collaboration fee prothena optin license fee zenas upfront license fee immatics upfront license optin fee note acquired iprd refer item financial statements supplementary datanote alliances note acquisitions divestitures licensing arrangements additional information amortization acquired intangible assets amortization acquired intangible assets decreased million primarily due abraxane marketed product right fully amortized fourth quarter incomeexpense net incomeexpense net changed billion primarily due litigation settlements equity investments items discussed year ended december dollars millions interest expense royalty licensing income royalty income divestitures equity investment lossesincome net integration expenses loss debt redemption divestiture gains litigation settlements investment income provision restructuring contingent consideration incomeexpense net interest expense decreased due additional debt maturities refer item financial statements supplementary datanote financing arrangements information royalties increased primarily due higher keytruda royalties refer item financial statements supplementary datanote acquisitions divestitures licensing arrangements information equity investments generated lower losses compared due fair value adjustments investments readily determinable fair value refer item financial statements supplementary datanote financial instruments fair value measurements information integration expenses decreased due lower consulting fees implement celgene integration initiatives related processes systems loss debt redemption resulted early redemption longterm debt billion divestiture gains resulted certain mature product rights divested investment income increased primarily due higher interest rates litigation settlements include million income related az settlement million income related nimbus ' tyk program change control provision partially offset million expense recorded connection beigene settlement litigation settlements include amounts related commercial disputes regarding licensing supply obligation matters intellectual property promotional practice matters refer item financial statementsnote incomeexpense net provision restructuring includes exit costs primarily related certain restructuring activities including new plan discussed item financial statements supplementary datanote restructuring income taxes year ended december dollars millions earnings income taxes provision income taxes effective tax rate impact specified items effective tax rate excluding specified items effective tax rate decreased primarily due impact specified items summarized following nongaap financial measures section significant impacts included million deferred income tax benefit following receipt nonus tax ruling regarding deductibility statutory impairment subsidiary investments ii million higher tax benefits attributed foreign currency net operating loss carryforwards iii million valuation allowance reversal related unrealized equity investment losses iv million tax benefit resulting revaluation basis intangible assets internally transferred streamline legal entity structure celgene acquisition v million tax reserve release related mead johnson splitoff transaction excluding impact specified items effective tax rate decreased primarily due revised guidance regarding deductibility certain research development expenses reduced income taxes attributable pretax income approximately million primary reason million reduction previously estimated income taxes upon finalization us federal income tax return ii favorable jurisdictional earnings mix partially offset iii million impact changes puerto rico tax decree eliminated previously creditable excise tax iv million lower income tax reserve reversals income tax reserve reversals included million related celgenes irs audits million tax positions effectively settled bms tax years excluding mead johnson related amounts specified lapse statute limitations celgene tax years refer item financial statements supplementary datanote income taxes additional information december eu member states voted unanimously adopt directive implementing pillar two global minimum tax rules giving member states december implement directive national legislation certain jurisdictions operate oecdg inclusive framework enacted legislation adopts subset rules effective january remaining rules becoming effective january rules associated legislative changes may significantly impact tax provision results operations implementation pillar two currently expected increase effective tax rate excluding specified items approximately nongaap financial measures nongaap financial measures nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative past future operating results items excluded nongaap earnings related eps information company believes neither relate ordinary course company 's business reflect company 's underlying business performance similar charges gains recognized prior periods likely reoccur future periods including amortization acquired intangible assets including product rights generate significant portion ongoing revenue recur intangible assets fully amortized ii unwind inventory purchase price adjustments iii acquisition integration expenses iv restructuring costs v accelerated depreciation impairment property plant equipment intangible assets vi costs acquiring priority review voucher vii divestiture gains losses viii stock compensation resulting acquisitionrelated equity awards ix pension legal contractual settlement charges x equity investment contingent value rights fair value adjustments including fair value adjustments attributed limited partnership equity method investments xi income resulting change control nimbus therapeutics tyk program xii amortization fair value adjustments debt acquired celgene exchange offer among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates certain significant tax items also excluded impact resulting nonus tax ruling regarding deductibility statutory impairment subsidiary investments release income tax reserves related mead johnson splitoff transaction internal transfers intangible assets streamline legal entity structure subsequent celgene acquisition also provide international revenues priority products excluding impact foreign exchange calculate foreign exchange impacts converting currentperiod local currency financial results using prior period average currency rates comparing adjusted amounts currentperiod results reconciliations nongaap measures comparable gaap measures included exhibit form k filed february incorporated herein reference nongaap information intended portray results baseline performance supplement enhance management analysts investors overall understanding underlying financial performance facilitate comparisons among current past future periods information intended considered isolation substitute related financial measures prepared accordance gaap may comparable similarly titled measures presented companies due possible differences method items adjusted encourage investors review financial statements publiclyfiled reports entirety rely single financial measure specified items follows year ended december dollars millions inventory purchase price accounting adjustments intangible asset impairment site exit costs cost products sold employee compensation charges site exit costs marketing selling administrative iprd impairments priority review voucher inventory purchase price accounting adjustments employee compensation charges site exit costs research development amortization acquired intangible assets interest expensea equity investment lossesgains net integration expenses loss debt redemption divestiture gains litigation settlements provision restructuring incomeexpense net increase pretax income income taxes items income taxes attributed internal transfer intangible assets income tax reserve release attributed mead johnson income taxes attributed nonus tax ruling income taxes increase net earnings includes amortization purchase price adjustments celgene debt reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms gaap specified items nongaap weightedaverage common shares outstanding diluted diluted earnings per share attributable bms gaap specified items nongaap financial position liquidity capital resources net debt position follows december dollars millions cash cash equivalents marketable debt securities current marketable debt securities noncurrent total cash cash equivalents marketable debt securities shortterm debt obligations longterm debt net debt position liquidity capital resources regularly assess anticipated working capital needs debt leverage ratio levels debt maturities capital expenditure requirements dividend payouts potential share repurchases future investments acquisitions order maximize shareholder return efficiently finance ongoing operations maintain flexibility future strategic transactions also regularly evaluate capital structure ensure financial risks adequate liquidity access lower cost capital efficiently managed may lead issuance additional debt securities repurchase debt securities prior maturity issuance repurchase common stock believe existing cash cash equivalents marketable debt securities together cash generated operations next years required issuance commercial paper sufficient satisfy anticipated cash needs least next years including dividends capital expenditures milestone payments working capital income taxes restructuring initiatives repurchase common stock debt maturities approximately billion well debt repurchases redemptions tender offers december net debt position decreased billion primarily driven billion cash provided operations partially offset billion dividend payments common stock repurchases billion capital expenditures february entered billion day senior unsecured delayed draw term loan facility provide bridge financing planned acquisitions karuna rayzebio facility would drawn acquisitions close prior planned issuance debt securities drawn would repaid following issuance securities amounts outstanding february information planned acquisitions refer item financial statements supplementary data note acquisitions divestitures licensing arrangements issued aggregate principal amount billion debt used net proceeds acquisition mirati january general corporate purposes addition billion debt matured repaid refer item financial statements supplementary data note financing arrangements information share repurchase program authorized board directors allowing repurchases bms common stock shares effected open market privately negotiated transactions compliance rule b exchange act including rule b trading plans share repurchase program obligate us repurchase specific number shares specific expiration date may suspended discontinued time repurchased approximately million shares common stock billion including approximately million shares billion asr agreements december board directors approved increase billion share repurchase authorization bms 's common stock remaining share repurchase capacity bms share repurchase program billion december refer item financial statements supplementary datanote equity additional information dividend payments billion billion dividend paid per common share quarter dividends authorized quarterly basis board directors commercial paper program may issue maximum billion unsecured notes maturities days date issuance commercial paper borrowings outstanding december december fiveyear billion revolving credit facility expiring january extendable annually one year consent lenders january extended credit facility january additionally february entered billion day revolving credit facility facilities provide customary terms conditions financial covenants may used provide backup liquidity commercial paper borrowings borrowings outstanding revolving credit facility december investment portfolio includes marketable debt securities subject changes fair value result interest rate fluctuations market factors investment policy establishes limits amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statements supplementary data note financing arrangements information capital expenditures annual capital expenditures approximately billion million expected approximately billion continue make capital expenditures connection expansion cell therapy manufacturing capabilities research development facilityrelated activities contractual obligations offbalance sheet arrangements normal course business enter contracts commitments obligate us make payments future information regarding obligations relating debt income taxes lease arrangements provided item financial statements supplementary datanote accounting policies recently issued accounting standards note financing arrangements note income taxes note leases respectively committed aggregate billion potential contingent future research development milestone payments third parties inlicensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical studies latestage milestones billion milestones achieved post phase iii clinical studies payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted certain agreements also provide salesbased milestones aggregating billion would obligated pay upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statements supplementary datanote alliances note acquisitions divestitures licensing arrangements information offbalance sheet arrangements material reasonably likely become material financial condition results operations credit ratings december following announcements acquire karuna rayzebio standard poor 's downgraded bms 's longterm credit rating stable longterm credit outlook changes shortterm standard poor credit rating downgrade longterm credit ratings reflects standard poor 's anticipation higher debt leverage following announced acquisitions partially offset improvements business strengths february moody 's confirmed bms 's longterm shortterm prime ratings negative longterm credit outlook collectively current longterm credit ratings reflect agencies opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm credit ratings reflect agencies opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally cash flows following discussion cash flow activities year ended december dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business million increase cash flow provided operating activities compared resulted billion lower us income tax payments primarily due revised guidance regarding deductibility certain research development expenses million higher noncustomer collections primarily due royalties interest litigation settlements impacts partially offset million lower net customer collections net rebates discounts million higher payments primarily due additional inventory requirements investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities original maturities greater days time purchase proceeds business divestitures including royalties sale maturity marketable securities sale equity investments well upfront contingent milestones payments licensing arrangements billion increase cash flow used investing activities compared resulted billion changes amount marketable debt securities held million lower divestiture proceeds partially offset acquisition turning point billion net cash acquired financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings well proceeds exercise stock options issuance longterm debt borrowings billion decrease cash used financing activities compared resulted billion changes net debt position primarily due billion issuance debt connection acquisition mirati lower debt maturities million billion lower share repurchases partially offset million lower proceeds stock option exercises recently issued accounting standards recently issued accounting standards refer item financial statements supplementary datanote accounting policies recently issued accounting standards sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy concerning sales direct customers purpose complying consent includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain dsas us pharmaceutical wholesalers account nearly gross us revenues current terms dsas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly affect financial condition results operations require difficult subjective complex judgments often need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized following five step model identify customer contract ii identify contracts performance obligation iii determine transaction price iv allocate transaction price performance obligation v recognize revenue performance obligation satisfied revenue also reduced gtn sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revise information actual experience following categories gtn adjustments involve significant estimates judgments information obtained external sources refer item financial statements supplementary datanote revenue discussion analysis significant category gtn sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries customers offered cash discounts incentive prompt payment generally approximating invoiced sales price accounts receivable reduced estimated amount cash discount time sale discount typically taken customer within one month medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount cms medicare part beneficiaries coverage gap estimated amount unpaid unbilled rebates discounts presented liability rebates returns discounts adjustments gtn sales adjustments include sales returns programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loss market exclusivity estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model estimated levels inventory distribution channel projected demand estimated amount product returns presented liability use information external sources information external sources used estimate gtn adjustments estimate inventory wholesalers based projected prescription demand based sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information acquisition intangible assets valuations make certain judgments determine whether transactions accounted acquisitions assets business combinations determined substantially fair value gross assets acquired transaction concentrated single asset group similar assets transaction treated acquisition assets evaluate inputs processes outputs associated acquired set activities assets assets transaction include input substantive process together significantly contribute ability create outputs transaction treated acquisition business account business combinations using acquisition method accounting requires assets acquired liabilities assumed generally recorded fair values acquisition date excess consideration fair value net assets acquired recorded goodwill estimating fair value requires us make significant judgments assumptions transactions accounted acquisitions assets goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date expensed unless alternative future use addition product development milestones expensed upon achievement identifiable intangible assets measured respective fair values acquisition date generally engage independent thirdparty valuation firm assist determining fair values assets acquisition date fair value assets estimated using discounted cash flow models models required use following significant estimates assumptions among others identification product candidates sufficient substance requiring separate recognition estimates revenues operating profits related commercial products product candidates eligible patients pricing market share used estimating future revenues probability success unapproved product candidates additional indications commercial products resources required complete development approval product candidates timing regulatory approvals exclusivity appropriate discount rate products market participant income tax rates allocation expected synergies products believe fair value used record intangible assets acquired based upon reasonable estimates assumptions considering facts circumstances acquisition date impairment amortization longlived assets including intangible assets longlived assets include intangible assets property plant equipment reviewed impairment whenever events changes circumstances indicate carrying amount assets may recoverable least annually iprd intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include changes competitive landscape earlier expected loss market exclusivity pricing reductions adverse regulatory changes clinical study results delay failure obtain regulatory approval initial follow indications unanticipated development costs inability achieve expected synergies resulting cost savings avoidance higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation carrying value longlived assets exceeds fair value asset written fair value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use estimated useful lives longlived assets subjective requires significant judgment regarding patent lives future plans external market factors longlived assets also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration depreciation amortization impairment charges included cost products sold research development expense million million billion refer item financial statements supplementary datanote goodwill intangible assets discussion analysis impairment charges income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowance million billion december net valuation allowance million us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes refer item financial statements supplementary datanote accounting policies recently issued accounting standardsincome taxes note income taxes contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statements supplementary datanote accounting policies recently issued accounting standardscontingencies note income taxes note legal proceedings contingencies product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance earlystage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represents approximately annual rd expenses last three years opdivo investigational compound marketed product represented approximately rd expenses last three years latestage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following latestage new indication developments marketed products well developments latestage pipeline february product indication date developments ono alliance partner opdivo japan announced submitted supplemental application opdivo intravenous infusion human antihuman pd monoclonal antibody japan expand use december treatment unresectable urothelial carcinoma partial change approved items manufacturing marketing approval application based results substudy phase iii checkmate trial announced fda accepted sbla opdivo combination cisplatinbased chemotherapy firstline treatment adult patients unresectable metastatic urothelial carcinoma bladder december application based results phase iii checkmate trial fda granted application priority review status assigned pdufa goal date april announced ema validated type ii variation application opdivo combination cisplatinbased chemotherapy firstline treatment adult patients unresectable metastatic october urothelial carcinoma application based results phase iii checkmate trial application validation confirms submission complete begins ema 's centralized review opdivo procedure announced fda approval opdivo adjuvant treatment adult pediatric patients years october older completely resected stage iib iic melanoma approval based phase iii checkmate k trial melanoma announced ec approval opdivo monotherapy adjuvant treatment adults adolescents august years age older stage iib iic melanoma undergone complete resection approval based results phase iii checkmate k trial ono alliance partner opdivo japan announced received supplemental approval opdivo intravenous infusion human antihuman pd monoclonal antibody japan expanded use treatment malignant mesothelioma excluding malignant pleural mesothelioma partial change malignant mesothelioma november approved items manufacturing marketing approval supplemental approval based results investigatorinitiated clinical phase ii viola trial product indication date developments announced followup results phase iii checkmate trial demonstrating sustained eventfree survival promising overall survival trends three cycles opdivo combination platinumbased chemotherapy neoadjuvant treatment patients resectable nsclc regardless pdl expression october levels neoadjuvant opdivo chemotherapy also showed improvements pathologic complete response major pathologic response chemotherapy alone pdl patient populations safety profile opdivobased regimen consistent across pdl subgroups nsclc announced first disclosure data phase iii checkmate trial evaluating perioperative regimen neoadjuvant opdivo chemotherapy followed surgery adjuvant opdivo patients resectable stage iia iiib nsclc showed statistically significant clinically meaning improvement october primary efficacy endpoint eventfree survival assessed blinded independent central review compared neoadjuvant chemotherapy placebo followed surgery adjuvant placebo announced ec approval opdivo combination platinumbased chemotherapy neoadjuvant treatment resectable nsclc high risk recurrence adult patients tumor cell pdl expression june approval based results phase iii checkmate trial nsclc ono alliance partner opdivo japan announced japan 's ministry health labour welfare 's march supplemental approval opdivo plus chemotherapy neoadjuvant treatment patients resectable nsclc approval based results phase iii checkmate trial announced results phase iii checkmate dx trial evaluating opdivo combination docetaxel patients advanced metastatic castrationresistant prostate cancer meet primary endpoints radiographic progressive free survival final analysis overall survival interim analysis prostate cancer july safety concerns reported based recommendation dmc company decided discontinue study opdivo announced data phase iii checkmate trial evaluating subcutaneous nivolumab coformulated halozymes proprietary recombinant human hyaluronidase compared intravenous opdivo patients advanced metastatic clear cell rcc received prior systemic therapy demonstrated non january inferiority coprimary endpoints cavgd timeaveraged opdivo serum concentration days cminss trough serum concentration steady state compared intravenous opdivo addition subcutaneous nivolumab displayed noninferior objective response rate assessed blinded independent central review versus intravenous opdivo announced fouryear followup results checkmate er trial evaluating opdivo combination cabometyx cabozantinib vs sunitinib patients previously untreated advanced metastatic rcc january continued show superior progressionfree survival objective response rates patients treated rcc opdivo plus cabometyx sunitinib regardless risk classification based imdc scores superior overall survival also observed patients treated combination announced phase iii checkmate noninferiority trial evaluating subcutaneous formulation opdivo coformulated halozyme therapeutics proprietary recombinant human hyaluronidase rhpuh subcutaneous nivolumab compared intravenous iv opdivo patients advanced metastatic clear cell renal cell carcinoma ccrcc received prior systemic therapy met coprimary october pharmacokinetics endpoints key secondary endpoint subcutaneous nivolumab demonstrated noninferiority cavgd timeaveraged opdivo serum concentration days cminss trough serum concentration steady state compared iv opdivo studys coprimary endpoints additionally subcutaneous nivolumab showed noninferior objective response rate assessed blinded independent central review vs iv opdivo key secondary endpoint safety profile subcutaneous nivolumab consistent iv formulation announced threeyear results phase iii checkmate trial demonstrating significant sustained clinical benefits opdivo adjuvant treatment patients surgically resected highrisk muscle uc february invasive uc continuous improvement diseasefree survival nonurothelial tract recurrencefree survival distant metastasisfree survival second progressionfree survival compared placebo across allrandomized patients patients whose tumor cells express pdl product indication date developments announced eightyear data phase iii checkmate trial evaluating opdivo plus yervoyversus sunitinib continued demonstrate longterm survival results reducing risk death patients previously untreated advanced metastatic rcc regardless imdc risk rcc january group patients treated opdivo plus yervoy maintained superior survival durable response benefits compared received sunitinib patients intermediate poorrisk prognostic factors across randomized patients announced phase iii checkmate hw trial evaluating opdivo plus yervoy compared investigators choice chemotherapy firstline treatment patients microsatellite instability high mismatch repair deficient metastatic colorectal cancer met dual primary endpoint progression free survival pfs assessed blinded independent central review bicr prespecific interim analysis study ongoing assess second dual primary endpoint pfs per bicr patients receiving opdivo plus yervoy compared opdivo alone across lines therapy well secondary metastatic colorectal opdivoyervoy cancer january endpoints addition data phase iii checkmate hw trial showed combination opdivo plus yervoy reduced risk disease progression death versus chemotherapy firstline treatment patients microsatellite instabilityhigh mismatch repair deficient metastatic colorectal cancer msihdmmr mcrc compared chemotherapy announced sixyear results phase iii checkmate trial demonstrating longterm durable september survival benefits opdivo plus yervoy compared chemotherapy firstline treatment patients metastatic nsclc regardless pdl expression levels nsclc announced fouryear followup results phase iii checkmate la trial demonstrating durable longterm survival benefits opdivo plus yervoy two cycles chemotherapy compared four june cycles chemotherapy alone previously untreated patients metastatic nsclc announced japan 's ministry health labour welfare granted manufacturing marketing approval reblozyl mdsrelated anemia approval based results global phase iii january commands trial phase iii medalist study well japanese phase ii study study mds red blood cell transfusionindependent lowrisk mds patients announced updated results primary analysis phase iii commands trial comparing reblozyl versus epoetin alfa treatment anemia erythropoiesis stimulating agent esanave mds december patients lowerrisk myelodysplastic syndromes may require red blood cell transfusions reblozyl confirmed positive outcome interim analysis superior efficacy durability compared esas announced fda approval reblozyl treatment anemia without previous erythropoiesis stimulating agent use esanave adult patients low intermediaterisk mds may august require regular red blood cell transfusions approval based phase iii commands trial announced ec approval reblozyl treatment adult patients anemia associated non beta thalassemia march transfusiondependent beta thalassemia approval based results phase ii beyond study phase iii relativity trial evaluating fixeddose combination nivolumab relatlimab treatment microsatellite stable metastatic colorectal cancer patients whose disease progressed following least one four prior lines therapy metastatic disease discontinued opdualag colorectal cancer december due futility based planned analysis conducted independent data monitoring committee determined trial unlikely meet primary endpoints upon completion recommendation stop study based safety concerns announced chmp ema recommended approval abecma earlier lines therapy tripleclass exposed relapsed refractory multiple myeloma chmp recommendation reviewed ec authority approve medicines eu recommendation approval abecma multiple myeloma january based phase iii karmma study abecma demonstrated superiority standard regimens significantly improved progressionfree survival wellestablished safety profile mostly lowgrade occurrences cytokine release syndrome neurotoxicity product indication date developments announced results preplanned final progressionfree survival analysis pivotal phase iii open december label global randomized controlled karmma study demonstrated significantly improved pfs maintained abecma compared standard regimens reduction risk disease progression death announced japan 's ministry health labour welfare granted manufacturing marketing approval supplemental new drug application additional indication abecma patients relapsed abecma multiple myeloma december refractory multiple myeloma received least two prior therapies including immunomodulatory agent proteasome inhibitor anticd antibody approval based interim analysis phase iii karmma study april announced alliance partner seventy bio fda accepted sbla abecma treatment adult patients relapsed refractory multiple myeloma received immunomodulatory agent proteasome inhibitor anticd monoclonal antibody announced data phase iii daybreak radiance trials showing eight years followup patients treated zeposia relapsing multiple sclerosis free sixmonth confirmed disability progression findings also demonstrated treatment zeposia resulted low rates progression independent relapse activity relapseassociated worsening key drivers disease progression zeposia multiple sclerosis october permanent disability multiple sclerosis also announced first interim readout phase iiib enlighten trial showing clinically meaningful improvement cognitive functioning compared baseline one year zeposia treatment almost half patients early relapsing multiple sclerosis announced fda accepted sblas breyanzi expand new indications include treatment adult patients relapsed refractory follicular lymphoma fl relapsed refractory mantle cell lymphoma mcl bruton tyrosine kinase inhibitor fda granted applications priority review assigned pdufa goal date may breyanzi relapsed refractory fl may breyanzi relapsed refractory mcl addition japan 's ministry health labour welfare also accepted company 's supplemental january new drug application snda breyanzi treatment relapsed refractory fl relapsed refractory fl applications breyanzi us japan based results transcend fl study relapsed refractory mcl application breyanzi us based results mcl cohort transcend nhl study breyanzi lymphoma announced first disclosure primary analysis results highrisk secondline cohort phase ii transcend fl study evaluating breyanzi patients relapsed refractory follicular lymphoma fl december demonstrated complete response patients highrisk relapsed refractory fl treated secondline setting announced fda accepted sbla breyanzi expand current indication include treatment adult patients relapsed refractory chronic lymphocytic leukemia small lymphocytic november lymphoma received prior bruton tyrosine kinase inhibitor bcell lymphoma inhibitor fda granted application priority review assigned pdufa goal date march announced ec approval breyanzi treatment adult patients diffuse large bcell lymphoma high grade bcell lymphoma primary mediastinal large bcell lymphoma fl grade b relapsed within may months completion refractory firstline chemoimmunotherapy approval based results phase iii transform trial product indication date developments announced results poetyk pso lte trial sotyktu treatment adult patients moderateto severe plaque psoriasis clinical response rates maintained continuous treatment modified nonresponder imputation responses psoriasis area severity index pasi years october continuous sotyktu treatment sotyktu consistent safety profile increases adverse events serious adverse events new safety signals sotyktu plaque psoriasis announced ec approval sotyktu treatment adults moderatetosevere plaque psoriasis candidates systemic therapy approval based phase iii poetyk pso poetyk march pso clinical trials well additional data poetyk pso longterm extension trial announced longterm followup results phase iii valorhcm lte trial demonstrating consistent impact oral treatment severely symptomatic obstructive hcm patients showing nearly patients treated camzyos continued trial without septal reduction therapy either weeks treatment august also announced results phase iii explorerlte trial showing treatment camzyos camzyos obstructive hcm demonstrated sustained improvements left ventricular outflow tract obstruction symptoms nt probnp levels patients symptomatic obstructive hcm new safety signals observed announced ec approval camzyos treatment symptomatic new york heart association class june iiiii obstructive hcm adult patients approval based results phase iii explorer hcm valorhcm trials augtyro announced fda approval augtyro treatment patients rospositive locally advanced nsclc november repotrectinib metastatic nsclc approval based phase iii trident trial ema validated marketing authorization application repotrectinib treatment ros tyrosine kinase inhibitor tkinave pretreated adult patients rospositive locally advanced repotrectinib nsclc january metastatic nsclc tkinave pretreated adult pediatric patients years older ntrkpositive locally advanced metastatic solid tumors application based results registrational phase iii trident trial care study announced alliance partner janssen pharmaceuticals inc johnson johnson company three prospective indications milvexian investigational oral factor xia inhibitor granted fast track designation fda designations cover three indicationseeking studies within phase iii milvexian thrombosis may librexia development program librexia stroke librexia acs librexia af dosing patients announced fda granted breakthrough therapy designation bms potential firstin class oral lysophosphatidic acid receptor lpa antagonist treatment progressive pulmonary progressive pulmonary fibrosis ppf breakthrough therapy designation based results global randomized phase ii bms lpa fibrosis october study assessed safety efficacy bms treatment versus placebo people living idiopathic pulmonary fibrosis ipf ppf stable background use antifibrotics ipf cohort andor select immunosuppressives ppf cohort allowed special note regarding forwardlooking statements including documents incorporated reference written oral statements make time time contain certain forward looking statements within meaning section securities act section e exchange act identify forwardlooking statements fact use words could expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations projections future financial results goals plans objectives involve inherent risks assumptions uncertainties including internal external factors could delay divert change next several years could cause future financial results goals plans objectives differ materially expressed implied statements statements likely relate among things goals plans objectives regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products business development strategy relation ability realize projected benefits acquisitions alliances business development activities impact pandemic epidemic operations development commercialization products potential laws regulations lower drug prices market actions taken private government payers manage drug utilization contain costs expiration patents data protection certain products including assumptions ability retain marketing exclusivity certain products outcome contingencies legal proceedings financial results forwardlooking statement guaranteed included important factors cautionary statements included particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made additional risks may currently deem immaterial presently known us could also cause forwardlooking events discussed occur except otherwise required applicable law undertake obligation publicly update revise forwardlooking statement whether result new information future events changed circumstances otherwise date item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen foreign currency forward purchased local currency put option contracts used manage risk primarily arising certain intercompany sales purchases transactions also exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated non us dollar currencies foreign currency forward contracts used offset exposures designated hedges foreign currency forward contracts also used hedge foreign currency exposures net investment certain international affiliates designated hedges net investments estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange contracts million million december december respectively reducing earnings remaining life contracts crosscurrency swap contracts used manage risk arising longterm debt denominated euros hedge company 's net investment foreign subsidiaries estimate appreciation underlying currencies hedged levels us dollar variables held constant would increase fair value crosscurrency swap contracts million december decrease million december respectively additional information refer item financial statements supplementary datanote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges provide appropriate balance fixed floating rate debt use cross currency swap contracts designated manage risk arising longterm debt denominated euros hedge company 's net investment foreign subsidiaries fair values contracts well marketable debt securities analyzed yearend determine sensitivity interest rate changes sensitivity analysis increase shortterm longterm interest rates december december expected adverse impact earnings would material estimate increase longterm interest rates december december would decrease fair value longterm debt billion billion respectively credit risk monitor investments counterparties objective minimizing concentrations credit risk investment policy invest institutions meet high credit quality standards establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statements supplementary datanote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products solda marketing selling administrative research development acquired iprd amortization acquired intangible assets incomeexpense net total expenses earnings income taxes provision income taxes net earnings noncontrolling interest net earnings attributable bms earnings per common share basic diluted excludes amortization acquired intangible assets consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits marketable debt securities foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable debt securities receivables inventories current assets total current assets property plant equipment goodwill intangible assets deferred income taxes marketable debt securities noncurrent assets total assets liabilities current liabilities shortterm debt obligations accounts payable current liabilities total current liabilities deferred income taxes longterm debt noncurrent liabilities total liabilities commitments contingencies equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million common shares total bms shareholders equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earningsloss net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges divestiture gains royalties acquired iprd equity investment lossesgains net contingent consideration fair value adjustments adjustments changes operating assets liabilities receivables inventories accounts payable rebates discounts income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable debt securities purchase marketable debt securities proceeds sales equity investment securities capital expenditures divestiture proceeds acquisition payments net cash acquired net cash used investing activities cash flows financing activities shortterm debt obligations net issuance longterm debt repayment longterm debt repurchase common stock dividends stock option proceeds net net cash used financing activities effect exchange rates cash cash equivalents restricted cash increasedecrease cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year cash cash equivalents restricted cash end year accompanying notes integral part consolidated financial statements note accounting policies recently issued accounting standards nature operations basis consolidation bristolmyers squibb company bms company global biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end definitions capitalized terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions consistent bmss operational structure chief executive officer ceo chief operating decision maker manages allocates resources global corporate level managing allocating resources global corporate level enables ceo assess overall level resources available best deploy resources across functions therapeutic areas regional commercial organizations research development projects line overarching longterm corporatewide strategic goals rather product franchise basis determination single segment consistent financial information regularly reviewed ceo purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information product regional revenue see note revenue use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates used determining accounting acquisitions impairments intangible assets chargebacks cash discounts sales rebates returns adjustments legal contingencies income taxes actual results may differ estimates cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper treasury bills money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable debt securities marketable debt securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity marketable debt securities reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition equity investments equity investments readily determinable fair values recorded fair value changes fair value recorded incomeexpense net equity investments without readily determinable fair values recorded cost minus impairment plus minus changes estimated fair value resulting observable price changes orderly transactions identical similar investment issuer changes estimated fair value equity investments without readily determinable fair values recorded incomeexpense net bms holds investments limited partnerships primarily invest earlystage life sciences companies limited partnership investments measured using proportionate share net asset values underlying investments held limited partnerships practical expedient investments typically redeemable distributions upon liquidation underlying assets limited partnerships investments less owned companies accounted using equity method accounting ability exercise significant influence operating financial decisions investee maintained proportional share investee 's net income losses equity investments accounted using equity method included incomeexpense net equity investments without readily determinable fair values equity investments accounted using equity method assessed potential impairment quarterly basis based qualitative factors inventory valuation inventories stated lower average cost net realizable value property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software ranging three ten years acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions assets acquired meet definition business primarily significant processes acquired substantially relative fair value allocated single asset transaction accounted asset acquisition rather business combination goodwill recorded addition asset acquisition acquired inprocess research development iprd assets alternative future use charged acquired iprd goodwill iprd intangible assets fair value acquired intangible assets determined using incomebased approach referred excess earnings method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success finitelived intangible assets including licenses marketed product rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized goodwill tested least annually impairment assessing qualitative factors determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include bmss share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment least annually frequently events occur circumstances change would indicate potential reduction fair values assets carrying value impairment charges recognized extent carrying value iprd determined exceed fair value derivatives derivative instruments recognized either assets liabilities fair value consolidated balance sheets classified current longterm based scheduled maturity instrument derivatives designated hedges assessed inception quarterly thereafter determine whether highly effective offsetting changes cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedged risk recognized earnings immediately effective portions changes fair value derivative designated cash flow hedge reported accumulated comprehensive loss subsequently recognized earnings consistent underlying hedged item derivative longer highly effective hedge company discontinues hedge accounting prospectively earnings impact related discontinued cash flow hedges hedge ineffectiveness material periods presented hedged forecasted transaction becomes probable occurring gains losses reclassified accumulated comprehensive loss earnings derivatives designated hedges adjusted fair value current earnings company also uses derivative instruments foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates realized unrealized gains losses hedges included foreign currency translation accumulated comprehensive loss derivative cash flows exception net investment hedges principally classified operating section consolidated statements cash flows consistent underlying hedged item cash flows related net investment hedges classified investing activities restructuring restructuring charges recognized result actions streamline operations realize synergies acquisitions reduce number facilities estimating impact restructuring plans including future termination benefits integration expenses exit costs requires judgment actual results could vary estimates restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets contingencies loss contingencies legal proceedings claims may occur government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred revenue recognition refer note revenue detailed discussion accounting policies related revenue recognition including deferred revenue royalties refer note alliances details regarding alliances research development acquired iprd research development costs expensed incurred clinical study certain research costs recognized service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred research development costs presented net reimbursements alliance partners acquired iprd expenses include upfront payments contingent milestone payments connection asset acquisitions inlicense arrangements thirdparty intellectual property rights well upfront contingent milestones payable bms alliance partners prior regulatory approval company 's acquired iprd type transaction follows year ended december dollars millions alliance note inlicense arrangements note acquired iprd advertising product promotion costs advertising product promotion costs expensed incurred advertising product promotion costs included marketing selling administrative expenses approximately billion billion foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive incomeloss income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax effects global intangible lowtaxed income certain foreign subsidiaries recognized income tax provision period tax arises tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement recently adopted accounting standards fair value measurements june fasb issued amended guidance measuring fair value equity security subject contractual restrictions prohibit sale equity security guidance clarifies contractual restriction sale equity security considered part unit account equity security therefore considered measuring fair value guidance also clarifies entity separate unit account recognize measure contractual sale restriction amendment requires following disclosures equity securities subject contractual sale restrictions fair value equity securities subject contractual sale restrictions reflected consolidated balance sheets nature remaining duration restrictions circumstances could cause lapse restrictions amended guidance effective january prospective basis early adoption permitted guidance adopted january adoption impact consolidated financial statements business combinations october fasb issued amended guidance accounting contract assets contract liabilities contracts customers business combination guidance intended address inconsistency related recognition acquired contract liability payment terms effect subsequent revenue recognized acquisition date entity account related revenue contracts accordance existing revenue recognition guidance generally assessing acquiree applied recognition measurement financial statements guidance adopted january adoption impact consolidated financial statements recently issued accounting standards yet adopted income taxes december fasb issued amended guidance income tax disclosures guidance intended provide additional disaggregation effective income tax rate reconciliation income tax payment disclosures amended guidance effective annual periods beginning january applied prospective basis early adoption permitted segment reporting november fasb issued amended guidance improvements reportable segment disclosures revised guidance requires public entity disclose significant segment expenses regularly reviewed chief operating decision maker codm including public entities single reportable segment amended guidance effective fiscal years beginning january interim periods beginning january retrospective basis early adoption permitted note revenue following table summarizes disaggregation revenue nature year ended december dollars millions net product sales alliance revenues revenues total revenues net product sales represent total revenues periods presented products sold principally wholesalers distributors specialty pharmacies lesser extent directly retailers hospitals clinics government agencies customer orders generally fulfilled within days receipt resulting minimal order backlog contractual performance obligations usually limited transfer control product customer transfer occurs either upon shipment upon receipt product considering customer obtains legal title product upon infusion cell therapies bms obtains right payment points customers able direct use obtain substantially remaining benefits product gross revenue three largest pharmaceutical wholesalers us percentage us gross revenues follows year ended december mckesson corporation cencora inc formerly known amerisourcebergen corporation cardinal health inc wholesalers initially invoiced contractual list prices payment terms typically days based customary practices country revenue reduced wholesaler list price time recognition expected chargebacks discounts rebates sales allowances product returns gtn adjustments us gtn adjustments attributed various commercial arrangements managed healthcare organizations government programs medicare medicaid b program containing various pricing implications mandatory discounts pricing protection wholesaler list price discounts medicare part beneficiaries coverage gap addition nonus government programs include different pricing schemes cost caps volume discounts outcomebased pricing pricing clawbacks determined sales individual companies aggregation companies participating specific market chargebacks cash discounts reflected reduction receivables settled issuance credits customer typically within one month gtn adjustments reflected liability settled cash payments customer typically within various time periods ranging months one year significant judgment required estimating gtn adjustments considering legal interpretations applicable laws regulations historical experience payer channel mix current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel following table summarizes gtn adjustments year ended december dollars millions gross product sales gtn adjustmentsa chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales includes adjustments provisions product sales made prior periods resulting changes estimates million million million alliance revenues consist primarily amounts related collaborations outlicensing arrangements arrangements evaluated whether represent contracts within scope revenue recognition guidance entirety contain aspects within scope guidance either directly reference based upon application guidance related derecognition nonfinancial assets asc performance obligations identified separated party benefit directly rights goods services either together readily available resources rights goods services highly interdependent interrelated transaction prices arrangements may include fixed upfront amounts well variable consideration contingent development regulatory milestones salesbased milestones royalties likely amount method used estimate contingent development regulatory salesbased milestones ultimate outcomes binary nature expected value method used estimate royalties broad range potential outcomes exist except instances royalties relate license variable consideration included transaction price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved significant judgment required estimating amount variable consideration recognize assessing factors outside bmss influence likelihood regulatory success limited availability third party information expected duration time resolution lack relevant past experience historical practice offering fee concessions large number broad range possible amounts extent arrangements include multiple performance obligations separable transaction price assigned distinct performance obligation reflective relative standalone selling price recognized point time upon transfer control three types outlicensing arrangements typically utilized arrangements bms outlicenses intellectual property another party performance obligations ii arrangements include license additional performance obligation supply product upon request third party iii collaboration arrangements include transferring license third party jointly develop commercialize product outlicensing arrangements consist single performance obligation satisfied upon execution agreement development commercialization rights transferred third party upfront fees recognized immediately included incomeexpense net although contingent development regulatory milestone amounts assessed period likelihood achievement typically constrained recognized uncertainty subsequently resolved full amount milestone included incomeexpense net salesbased milestones royalties recognized milestone achieved subsequent sales occur salesbased milestones royalties included alliance revenues certain outlicensing arrangements may also include contingent performance obligations supply commercial product third party upon request license supply obligations accounted separate performance obligations considered distinct third party benefit license either together supply resources readily available obligations separately identifiable obligations contract accordance revenue recognition guidance considering standalone selling prices situations upfront fees contingent development regulatory milestone amounts salesbased milestone royalties allocated license recognized manner described consideration supply obligation usually based upon stipulated costplus margin contractual terms represent standalone selling price supply consideration recognized point time upon transfer control product third party included alliance revenues fee allocation license supply represents amount consideration expected entitled satisfaction separate performance obligations although collaboration arrangements unique nature parties active participants operating activities exposed significant risks rewards depending commercial success activities performance obligations inherent arrangements may include transfer certain development commercialization rights ongoing development commercialization services product supply obligations except certain product supply obligations considered distinct accounted separate performance obligations similar manner discussed performance obligations considered distinct combined single performance obligation since transferred rights highly integrated interrelated obligation jointly develop commercialize product third party result upfront fees recognized ratably time throughout expected period collaboration activities included incomeexpense net license combined development commercialization obligations contingent development regulatory milestones longer constrained recognized similar manner prospective basis royalties profit sharing recognized underlying sales profits occur included alliance revenues refer note alliances information following table summarizes disaggregation revenue product region year ended december dollars millions inline products eliquis opdivo orencia pomalystimnovid yervoy sprycel mature brands total inline products new product portfolio reblozyl opdualag abecma zeposia breyanzi camzyos sotyktu onureg inrebic augtyro total new product portfolio total inline products new product portfolio recent loe productsa revlimid abraxane total recent loe products total revenues united states international otherb total revenues recent loe products include products significant expected decline revenue prior reporting period result loe b include royalties alliancerelated revenues products sold bmss regional commercial organizations contract assets primarily estimated future royalties termination fees eligible licensing exclusion therefore recognized asc asc contract assets reduced receivables increased period underlying sales occur cumulative catchup adjustments revenue affecting contract assets contract liabilities material years ended december revenue recognized performance obligations satisfied prior periods million million million consisting primarily revised estimates gtn adjustments related prior period sales royalties outlicensing arrangements sales commissions incremental costs obtaining customer contracts expensed incurred amortization periods would less one year note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions bms refers collaborations alliances partners alliance partners common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bmss contractual share thirdparty sales andor royalty income included alliance revenues sale commercial products considered part bmss ongoing major central operations refer note revenue information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenues sale commercial products considered part bmss ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development regulatory approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized expected period bms 's development copromotion obligation market exclusivity period periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense net activities performed time related sale commercial products included bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations upfront contingent regulatory approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included acquired iprd expense royalties contingent consideration payable bms alliance partners related divestiture businesses included incomeexpense net earned payments bms alliance partners presented cash flows operating activities except upfront milestone payments presented cash flows investing activities selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development acquired iprd incomeexpense net selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone payments specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections statements earnings classification amounts attributable payments parties systimmune december bms systimmune inc systimmune announced global strategic collaboration codevelopment cocommercialization bl bd bispecific topoisomerase inhibitorbased antibody drug conjugate targets egfr currently evaluated phase clinical trial metastatic unresectable nsclc parties jointly develop commercialize blbd us profits research development commercialization costs shared us systimmune responsible development commercialization manufacturing mainland china responsible manufacturing certain drug supplies outside mainland china bms receive royalty net sales bms responsible development commercialization rest world systimmune receive royalty net sales transaction became effective february included upfront payment million included acquired iprd first quarter bms also obligated pay billion upon achievement contingent development regulatory salesbased milestones pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms sales based fee coexclusive license rights granted pfizer exchange upfront payment potential milestone payments recorded deferred income amortized incomeexpense net eliquis commercial product commencement alliance upfront payment subsequent contingent milestone proceeds amortized expected period bms 's copromotion obligation market exclusivity period parties assumed certain obligations actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms pfizer manufacture product alliance bms principal end customer product sales us significant countries europe well canada australia china japan south korea certain smaller countries pfizer full commercialization rights bms supplies product pfizer cost plus percentage net sales price endcustomers recorded full upon transfer control product pfizer summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing incomeexpense net amortization deferred income selected alliance balance sheet information december dollars millions receivables accounts payable deferred income ono bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues bms principal end customer product sales exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan ono entitled receive royalties north america territories excluding three countries listed subject customary adjustments bridgebio bms bridgebio commenced collaboration develop commercialize bbp shp inhibitor oncology transaction included upfront payment million expensed acquired iprd bridgebio eligible receive contingent development regulatory salesbased milestones million well royalties global net sales excluding certain markets bridgebio responsible funding completing ongoing bbp phase monotherapy combination therapy trials bms lead fund development commercial activities bridgebio option codevelop bbp receive higher royalties us seventy bio bms seventy bio jointly develop commercialize novel diseasealtering gene therapy product candidates targeting bcma collaboration includes right bms license antibcma products resulting collaboration ii right seventy bio participate development commercialization licensed products resulting collaboration codevelopment profit share us exchange reduction milestone payments iii salesbased milestones royalties payable seventy bio upon commercialization licensed products resulting collaboration seventy bio decline exercise codevelopment profit sharing rights bms exercised option license idecabtagene vicleucel abecma seventy bio elected participate development commercialization abecma us terms collaboration since amended transfer substantially manufacturing obligations bms eliminate exus milestones royalties payable seventy bio abecma fda approved abecma treatment relapsed refractory multiple myeloma net product sales abecma us million million million related profit sharing costs million million million respectively cost reimbursements material eisai bms eisai commenced exclusive global strategic collaboration codevelopment cocommercialization morab selective folate receptor alpha antibodydrug conjugate investigated endometrial ovarian lung breast cancers morab currently phase iii clinical trials solid tumors parties jointly develop commercialize morab us canada europe russia japan china certain countries asiapacific region collaboration territory eisai responsible global manufacturing supply profits research development commercialization costs shared collaboration territories bms responsible development commercialization outside collaboration territory pay royalty sales million upfront collaboration fee expensed acquired iprd bms also obligated pay billion upon achievement contingent development regulatory salesbased milestones cost reimbursements material note acquisitions divestitures licensing arrangements acquisitions mirati january bms acquired mirati commercial stage targeted oncology company pipeline clinical commercial oncology medicines acquisition bms added commercialized lung cancer medicine krazati well several clinical assets including mrtx krazati bestinclass inhibitor krasgc mutation approved fda secondline treatment patients nsclc clinical development combination pd inhibitor firstline therapy patients nsclc well indications mrtx potential firstinclass mtacooperative prmt inhibitor phase development bms also gained access several promising clinical preclinical stage assets including additional kras inhibitors enabling programs bms acquired issued outstanding shares mirati 's common stock per share allcash transaction total consideration billion billion net estimated cash acquired mirati stockholders also receive one nontradeable contingent value right share mirati common stock held potentially worth per share cash total value approximately billion payout contingent value right subject fda acceptance nda mrtx treatment specific indications within seven years closing transaction transaction accounted business combination assets acquired liabilities assumed recognized fair value acquisition date purchase price allocation consideration transferred assets acquired liabilities assumed yet finalized acquisition funded combination cash hand debt proceeds karuna december bms entered definitive merger agreement acquire karuna clinicalstage biopharmaceutical company driven discover develop deliver transformative medicines people living psychiatric neurological conditions acquisition provide bms rights karuna 's lead asset karxt xanomelinetrospium karxt antipsychotic novel mechanism action differentiated efficacy safety currently review fda treatment schizophrenia adults pdufa date september karxt also registrational trials adjunctive therapy existing standard care agents schizophrenia treatment psychosis patients alzheimers disease bms acquire issued outstanding shares karuna 's common stock per share allcash transaction total consideration billion accounting treatment business combination asset acquisition determined period transaction closes transaction expected close first half subject customary closing conditions including approval karuna stockholders receipt regulatory approvals acquisition funded primarily future debt proceeds rayzebio december bms entered definitive merger agreement acquire rayzebio clinicalstage radiopharmaceutical therapeutics rpt company actiniumbased rpts solid tumors acquisition provide bms rights rayzebios actiniumbased radiopharmaceutical platform lead asset ryz phase iii development treatment gastroenteropancreatic neuroendocrine tumors bms acquire issued outstanding shares rayzebio 's common stock per share allcash transaction total consideration billion transaction expected accounted business combination anticipated close first half subject fulfillment customary closing conditions including receipt required regulatory approvals acquisition funded primarily future debt proceeds orum november bms acquired rights orum 's orm program preclinical development orm anticd antibodyenabled gspt degrader received fdas clearance phase treatment patients acute myeloid leukemia highrisk myelodysplastic syndromes consideration included upfront payment million well contingent development milestone payments million upfront payment expensed acquired iprd turning point bms acquired turning point billion cash billion net cash acquired turning point clinicalstage precision oncology company pipeline investigational medicines designed target common mutations alterations drive cancer growth acquisition provided bms rights turning point 's lead asset repotrectinib clinical preclinical stage assets repotrectinib approved fda november marketed brand name augtyro transaction accounted business combination assets acquired liabilities assumed recognized fair value acquisition date total consideration acquisition consisted following dollars millions cash consideration outstanding shares cash consideration equity awards consideration paid less unvested stock awards total consideration allocated included unvested equity awards million expensed marketing selling administrative million expensed research development purchase price allocation resulted following amounts allocated assets acquired liabilities assumed acquisition date based upon respective fair values summarized dollars millions cash cash equivalents current assets intangible assets deferred income tax assets noncurrent assets deferred income tax liabilities current liabilities identifiable net assets acquired goodwill b total consideration allocated intangible assets included billion iprd allocated repotrectinib augtyro estimated fair value iprd assets determined using income approach valuation method b goodwill resulted primarily recognition deferred tax liabilities deductible tax purposes results turning point 's operations included consolidated financial statements commencing august material historical financial results acquired entity significant divestitures following table summarizes financial impact divestitures including royalty income included incomeexpense net revenue pretax earnings related divestitures material periods presented excluding divestiture gains losses net proceeds divestiture gainslosses royalty income dollars millions diabetes business royalties mature products othera total includes cash proceeds million divestiture gain million related sale several mature products cheplapharm diabetes business bms astrazeneca terminated diabetes business alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance consideration transaction included tiered royalty payments ranging based net sales royalties million million million bms transferred percentage future royalty rights amylin onglyza farxiga net product sales third parties result transfers royalty income associated products reduced million million million mature products manufacturing operations bms agreed sell manufacturing facility syracuse new york lotte corporation accounted business heldforsale resulted million impairment charge recorded cost products sold assets liabilities reclassified heldforsale included within current assets current liabilities million million respectively december january bms completed sale resulting cash proceeds million received december licensing arrangements royalty licensing income following table summarizes financial impact keytruda royalties tecentriq royalties upfront licensing fees milestones products obtained commercial approval included incomeexpense net year ended december dollars millions keytruda royalties tecentriq royalties upfront licensing fees contingent milestone income amortization deferred income biohaven sublicense income royalties total lianbio mavacamten october bms reacquired rights mavacamten china certain asian territories lianbio transaction resulted million acquired iprd charge included cash transferred million carrying value previously established license intangible asset keytruda patent license agreement bms ono parties global patent license agreement merck related merck 's pd antibody keytruda agreement merck obligated pay ongoing royalties global sales keytruda december pay january december companies also granted certain rights respective patent portfolios pertaining pd payments royalties shared bms ono percent allocation respectively adjusting parties ' legal fees tecentriq patent license agreement bms ono parties global patent license agreement roche group related tecentriq roches antipdl antibody agreement roche obligated pay singledigit royalties worldwide net sales tecentriq december royalties shared bms ono consistent existing agreements inlicense arrangements immatics bms obtained global exclusive license immatics ' tcr bispecific ima program studied oncology bms immatics collaborate development bms responsible commercialization ima worldwide including strategic decisions regulatory responsibilities funding manufacturing immatics option cofund us development exchange enhanced us royalty payments andor copromote ima us transaction included upfront payment million expensed acquired iprd immatics eligible receive contingent development regulatory salesbased milestones million well royalties global net sales agenus bms obtained global exclusive license agenus proprietary agen bispecific antibody program blocks tigit additional target agen studied oncology bms responsible development subsequent commercialization agen related products worldwide including strategic decisions regulatory responsibilities funding manufacturing transaction included payment million expensed acquired iprd addition agenus eligible receive contingent development regulatory salesbased milestones billion well royalties global net sales dragonfly bms obtained global exclusive license dragonflys interleukin il investigational immunotherapy program phase development milestone il achieved resulting million payment dragonfly expensed acquired iprd bms notified dragonfly terminating global exclusive license relates dragonflys il program rights reverted back dragonfly bms amended terms license arrangement paid third party million extinguish future royalty obligation related camzyos mavacamten prior fda approval april resulting acquired iprd charge note incomeexpense net year ended december dollars millions interest expense royalty licensing income note royalty income divestitures note equity investment lossesgains net note integration expenses note loss debt redemption note divestiture gains note litigation settlements investment income provision restructuring note contingent consideration incomeexpense net litigation settlements beigene settlement bms beigene ltd beigene entered agreement settled ongoing disputes claims parties including related abraxane license supply agreements related arbitration proceedings described note legal proceedings contingencies agreement also provided termination contractual relationships parties including license supply arrangements pertaining revlimid vidaza effective december subject beigenes right continue sell remaining inventory beyond date consideration bms agreed transfer million beigene ordinary shares common stock held share subscription agreement back beigene resulting million expense included incomeexpense net expense determined based closing price shares date transfer addition remaining beigene ordinary shares owned bms share subscription agreement converted american depository shares subsequently sold astrazeneca settlement bms entered agreement astrazeneca settle outstanding claims parties ctla litigation two pdl antibody litigations described note legal proceedings contingencies astrazeneca pay aggregate million bms four payments september subject sharing arrangements ono danafarber bms 's share approximately million net present value million reflected incomeexpense nimbus change control income bms nimbus entered settlement resolving legal claims business interests pertaining nimbus ' tyk inhibitor resulting million income included incomeexpense settlement also provides bms receive additional amounts contingent development regulatory approval salesbased milestones change control proceeds received nimbus related tyk inhibitor takeda acquired ownership nimbus ' tyk inhibitor approximately billion upfront proceeds plus contingent salesbased milestones aggregating billion result million income related change control provision included incomeexpense contingent consideration contingent consideration included million fair value adjustments resulting change traded price contingent value rights issued celgene acquisition contractual obligation pay contingent value rights terminated january fda approve lisocel jcar december note restructuring restructuring plan bms commenced restructuring plan accelerate delivery medicines patients evolving streamlining enterprise operating model key areas rd manufacturing commercial functions ensure operating model supports appropriately aligned companys strategy invest key priorities changes primarily include transforming rd operations accelerate pipeline delivery ii enhancing commercial operating model iii establishing responsive manufacturing network expanding cell therapy manufacturing capabilities charges approximately billion expected incurred consisting primarily employee termination costs lesser extent site exit costs including impairment accelerated depreciation property plant equipment celgene acquisition plans restructuring integration plans initiated realize expected cost synergies resulting cost savings avoidance acquisition celgene myokardia turning point part plans company expects incur charges approximately billion cumulative charges approximately billion recognized date including integration planning execution expenses employee termination benefit costs accelerated stockbased compensation contract termination costs shutdown costs associated site exits remaining charges primarily related celgene 's system integration following provides charges related restructuring initiatives type cost year ended december dollars millions restructuring plan celgene acquisition plans total charges employee termination costs termination costs provision restructuring integration expenses accelerated depreciation asset impairments shutdown costs net total charges cost products sold marketing selling administrative research development incomeexpense net total charges following summarizes charges spending related restructuring plan activities year ended december dollars millions liability january provision restructuringa payments foreign currency translation liability december includes reductions liability resulting changes estimates million million note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision income taxes effective tax rate reconciliation effective tax rate us statutory federal income tax rate follows earnings income taxes dollars millions earnings income taxes us nonus total us statutory rate gilti net foreign derived intangible income deduction foreign tax effect certain operations ireland puerto rico switzerland nonus tax ruling internal transfers intangible assets us federal valuation allowance us federal state foreign contingent tax matters us federal researchbased credits charitable contributions inventory contingent value rights puerto rico excise tax credit state local taxes net valuation allowance foreign total provision income taxes gilti net foreign derived intangible income deduction includes benefit approximately million due revised guidance regarding deductibility certain research development expenses foreign tax effect certain operations ireland puerto rico switzerland includes impact earnings mix million benefit impact foreign currency net operating loss carryforwards nonus tax ruling includes million deferred income tax benefit regarding deductibility statutory impairment subsidiary investments internal transfers intangible assets streamline legal entity structure subsequent celgene acquisition resulted tax benefit us federal valuation allowance includes million reversal related unrealized equity investment losses us federal state foreign contingent tax matters include tax benefits related lapse statute effectively settled contingent tax matters million million us federal researchbased credits includes credits research development well orphan drug credits include revised estimates upon finalization prior year tax returns fair value adjustments contingent value rights taxable tax deductible puerto rico imposed excise tax gross company purchase price goods sold bmss manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurred us income tax purposes excise tax deductible resulted foreign tax credits generally recognized bmss provision income taxes excise tax incurred december bms amended existing puerto rico decree eliminating excise tax increasing puerto rico tax rate effective tax year beginning january extending bmss tax grants additional years deferred taxes valuation allowance components deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards state net operating loss credit carryforwards us federal capital loss net operating loss tax credit milestone payments license fees capitalized research expenditures total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities acquired intangible assets goodwill total deferred tax liabilities deferred tax assetsliabilities net recognized deferred income taxes assets noncurrent deferred income taxes liabilities noncurrent total bms indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign state income withholding tax would apply bms remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable foreign net operating loss carryforwards includes impact nonus tax ruling regarding deductibility statutory impairment subsidiary investments us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance million exists following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal deferred tax assets including equity investment fair value adjustments us federal net operating loss carryforwards changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitionsdispositionsliquidations net nonus rate change balance end year certain foreign net operating losses related valuation allowances utilized eliminated result internal legal entity restructurings income tax payments billion billion billion connection enactment tcja required pay onetime transition tax elected pay period eight years permitted tcja remaining amounts payable follows million billion million business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credit deductibility certain expenses deemed repatriation transition tax liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows excluding interest penalties year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest penalties expensebenefit accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense amounts reflect beneficial impacts various tax settlements including settlement discussed bms currently examination number tax authorities proposed considering proposing material adjustments tax positions issues transfer pricing certain tax credits deductibility certain expenses previously disclosed bms received several notices proposed adjustments irs related transfer pricing tax issues tax years bms disagrees irss positions continues work cooperatively irs resolve issues bms entered irs administrative appeals process resolve matters timing final resolution complex matters uncertain could material impact bmss financial statements tax positions years unrelated matters entered administrative appeals process considered effectively settled reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction also reasonably possible total amount unrecognized tax benefits december could decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits may result payment additional taxes adjustment certain deferred taxes andor recognition tax benefits following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy japan uk note earningsloss per share year ended december amounts millions except per share data net earnings attributable bms weightedaverage common shares outstanding basic incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per common share basic diluted total number potential shares common stock excluded diluted earnings per share computation antidilutive impact material note financial instruments fair value measurements financial instruments include cash cash equivalents marketable debt securities equity investments accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective nav underlying investments level derivative instruments valued using sofr yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract fair value level equity investments adjusted characteristics specific security adjusted contractual sale restrictions equity investments subject contractual sale restrictions material december level unobservable inputs used little market data available level financial liabilities consist acquisition related contingent consideration success payments related undeveloped product rights transfers levels year ended december financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level level level cash cash equivalents money market securities marketable debt securities certificates deposit commercial paper corporate debt securities us treasury securities derivative assets equity investments derivative liabilities contingent consideration liability contingent value rights acquisition related contingent consideration marketable debt securities amortized cost marketable debt securities approximates fair value securities mature within four years december one year december equity investments following summarizes carrying amount equity investments december dollars millions equity investments readily determinable fair values equity investments without readily determinable fair values limited partnerships equity method investments total equity investments following summarizes activity related equity investments changes fair value equity investments included incomeexpense net year ended december dollars millions equity investments readily determined fair values net loss recognized net gain recognized investments sold net unrealized loss recognized investments still held equity investments without readily determinable fair values upward adjustments impairments downward adjustments equity net incomeloss affiliates total equity investment lossesgains cumulative upwards adjustments cumulative impairments downward adjustments based observable price changes equity investments without readily determinable fair values still held december million million respectively qualifying hedges nonqualifying derivatives cash flow hedges bms enters foreign currency forward purchased local currency put option contracts foreign exchange contracts hedge certain forecasted intercompany inventory sales certain foreign currency transactions objective foreign exchange contracts reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheets changes fair value foreign exchange contracts designated cash flow hedges temporarily recorded accumulated comprehensive loss aocl reclassified net earnings hedged item affects earnings typically within next months december assuming market rates remain constant contract maturities expect reclassify pretax gains million cost products sold foreign exchange contracts aocl next months notional amount outstanding foreign currency exchange contracts primarily billion euro contracts billion japanese yen contracts december bms also enters crosscurrency swap contracts hedge exposure foreign currency exchange rate risk associated longterm debt denominated euros contracts convert interest payments principal repayment longterm debt us dollars euros designated cash flow hedges unrealized gains losses contracts reported aocl reclassified incomeexpense net periods hedged debt affects earnings notional amount crosscurrency interest rate swap contracts associated longterm debt denominated euros billion december cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis earnings impact related discontinued cash flow hedges hedge ineffectiveness material periods presented foreign currency exchange contracts designated cash flow hedge offset exposures certain foreign currency denominated assets liabilities earnings changes fair value derivatives recognized earnings occur net investment hedges crosscurrency swap contracts foreign currency forward contracts million december designated hedge currency exposure bms 's net investment foreign subsidiaries contract fair value changes recorded foreign currency translation component aocl related offset derivative asset liability consolidated balance sheets notional amount outstanding crosscurrency swap foreign currency forward contracts primarily attributed japanese yen million euro million december years ended december amortization gains related portion net investment hedges excluded assessment effectiveness material fair value hedges fixed floating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value gains losses resulting changes fair value underlying debt attributable hedged benchmark interest rate risk recorded interest expense associated offset carrying value debt since specific terms notional amount swap intended align debt hedged changes fair value swap recorded interest expense associated offset derivative asset liability consolidated balance sheet result net impact earnings underlying swap terminated prior maturity fair value adjustment underlying debt amortized reduction interest expense remaining term debt derivative cash flows exception net investment hedges principally classified operating section consolidated statements cash flows consistent underlying hedged item cash flows related net investment hedges classified investing activities following summarizes fair value outstanding derivatives december december asseta liabilityb asseta liabilityb dollars millions notional fair value notional fair value notional fair value notional fair value designated cash flow hedges foreign exchange contracts crosscurrency swap contracts designated net investment hedges foreign exchange contracts crosscurrency swap contracts designated fair value hedges interest rate swap contracts designated hedges foreign currency exchange contracts total return swap contractsc included current assets noncurrent assets b included current liabilities noncurrent liabilities c total return swap contracts entered hedge changes fair value certain deferred compensation liabilities following table summarizes financial statement classification amount gainloss recognized hedging instruments year ended december cost incomeexpense cost incomeexpense cost incomeexpense dollars millions products sold net products sold net products sold net interest rate swap contracts crosscurrency swap contracts foreign exchange contracts following table summarizes effect derivative nonderivative instruments designated hedging instruments comprehensive incomeloss year ended december dollars millions derivatives qualifying cash flow hedges foreign exchange contracts gainloss recognized comprehensive incomeloss reclassified cost products sold crosscurrency swap contracts gainloss recognized comprehensive income reclassified incomeexpense net forward starting interest rate swap contract loss reclassified incomeexpense net derivatives qualifying net investment hedges crosscurrency swap contracts gainloss recognized comprehensive incomeloss foreign exchange contracts gainloss recognized comprehensive incomeloss nonderivatives qualifying net investment hedges nonus dollar borrowings gainloss recognized comprehensive incomeloss company dedesignated remaining net investment hedge debt denominated euros million amount represents effective portion foreign exchange loss remeasurement debt note financing arrangements shortterm debt obligations include december dollars millions nonus shortterm borrowings current portion longterm debt total longterm debt current portion longterm debt includes december dollars millions principal value notes due notes due notes due notes due notes due notes due notes due notes due euro notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due euro notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due convertible debt due total december dollars millions principal value adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs unamortized purchase price adjustments celgene debt total current portion longterm debt longterm debt total fair value longterm debt billion billion december respectively valued using level inputs based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments february entered billion day senior unsecured delayed draw term loan facility provide bridge financing planned acquisitions karuna rayzebio facility would drawn acquisitions close prior planned issuance debt securities drawn would repaid following issuance securities amounts outstanding february bms issued aggregate principal amount billion fixed rate unsecured senior notes company used net proceeds offering finance acquisition mirati january general corporate purposes bms issued aggregate principal amount billion fixed rate unsecured senior notes net proceeds billion notes rank equally right payment bmss existing future senior unsecured indebtedness redeemable time whole part varying specified redemption prices plus accrued unpaid interest bms purchased aggregate principal amount billion certain debt securities billion cash series tender offers make whole redemptions connection transactions million loss debt redemption recognized based carrying value debt included incomeexpense net bms purchased aggregate principal amount billion certain debt securities approximately billion cash series tender offers make whole redemptions connection transactions million loss debt redemption recognized based carrying value debt included incomeexpense net repayment notes maturity aggregated billion billion billion interest payments billion billion billion aggregate maturities longterm debt next five years follows billion billion billion billion billion interest payments related longterm debt next five years follows billion billion billion billion billion credit facilities december bms fiveyear billion revolving credit facility expiring january extendable annually one year consent lenders january extended credit facility january additionally february entered billion day revolving credit facility facilities provide customary terms conditions financial covenants may used provide backup liquidity bms commercial paper borrowings borrowings outstanding revolving credit facility december available financial guarantees provided form bank overdraft facilities standby letters credit performance bonds billion december standby letters credit guarantees issued financial institutions support various obligations including sale products hospitals foreign ministries health bonds customs duties vat note receivables december dollars millions trade receivables less chargebacks cash discounts less allowance expected credit loss net trade receivables alliance royalties vat receivables nonus receivables sold nonrecourse basis billion billion billion aggregate receivables three pharmaceutical wholesalers us represented approximately total trade receivables december respectively changes allowances expected credit loss chargebacks cash discounts follows year ended december dollars millions balance beginning year provisiona utilization balance end year includes provision expected credit loss million million million note inventories december dollars millions finished goods work process raw packaging materials total inventories inventories noncurrent assets total inventories include fair value adjustments resulting celgene acquisition approximately million december note property plant equipment december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment united states international total depreciation expense million million million note leases leased facilities office research development storage distribution purposes comprise approximately total lease obligation lease terms vary based nature operations market dynamics country however leased facilities classified operating leases remaining lease terms one year years leases contain specific renewal options periods ranging one year years notice renew must provided advance lease expiration automatic renewals advance notice required periods covered option extend lease included noncancellable lease term exercise option determined reasonably certain certain leases also contain termination options provide flexibility terminate lease ahead expiration sufficient advance notice periods covered option terminate lease included non cancellable lease term exercise option determined reasonably certain judgment required assessing whether renewal termination options reasonably certain exercised factors considered contractual terms compared current market rates leasehold improvements expected significant value costs terminate lease importance facility operations costs determined variable based index rate included measurement real estate lease liabilities variable costs include real estate taxes insurance utilities common area maintenance operating costs implicit rate leases readily determinable incremental borrowing rate applied portfolio approach discount real estate lease liabilities remaining lease obligations comprised vehicles research development facility operated third party managements direction vehicle lease terms vary country terms generally one year four years following table summarizes components lease expense year ended december dollars millions operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse assets liabilities follows december dollars millions noncurrent assets current liabilities noncurrent liabilities total liabilities future lease payments noncancellable operating leases december follows dollars millions thereafter total future lease payments less imputed interest total lease liability rightofuse assets obtained exchange new operating lease obligations million rightofuse assets impairment charge million cash paid amounts included measurement operating lease liabilities million million million undiscounted lease obligations operating leases yet commenced million december obligation primarily relates research development facility constructed lessor expected ready use supplemental balance sheet information related leases follows december weighted average remaining lease term years years weighted average discount rate note goodwill intangible assets goodwill changes carrying amounts goodwill follows december dollars millions beginning balance turning point acquisition currency translation adjustments ending balance intangible assets intangible assets consisted following december estimated gross carrying accumulated intangible gross carrying accumulated intangible dollars millions useful lives amounts amortization assets net amounts amortization assets net licenses years acquired marketed product rights years capitalized software years iprd total november billion iprd previously allocated repotrectinib augtyro transferred acquired marketed product rights upon obtaining fda approval refer note acquisitions divestitures licensing arrangements information related turning point acquisition december bms agreed pay million former shareholders impact biomedicines extinguish remaining contingent milestone obligations recorded acquired marketed product rights inrebic amount million establishing applicable deferred tax liability million paid january amortization expense intangible assets billion billion billion future annual amortization expense intangible assets expected approximately billion billion billion billion billion intangible asset impairment charges million million billion impairment charges primarily resulted decisions discontinue development investigational compounds connection prioritization current pipeline opportunities million iprd impairment charge investigational compound recorded research development expense primarily resulting changes clinical timelines expected launch dates competitive landscape compound studied potential treatment hematologic diseases acquired acquisition celgene charge represented partial writedown carrying value based estimated fair value determined using discounted cash flow projections million iprd impairment charge recorded research development expense following decision discontinue development investigational compound connection prioritization pipeline opportunities compound studied potential treatment fibrotic diseases acquired acquisition celgene charge represented full writedown based estimated fair value determined using discounted cash flow projections inrebic eu regulatory approval milestones million achieved resulting million increase acquired marketed product rights intangible asset establishing applicable deferred tax liability impairment charge million recognized cost products sold carrying value asset exceeded projected undiscounted cash flows asset charge equal excess asset 's carrying value estimated fair value using discounted cash flow projections note supplemental financial information december dollars millions income taxes research development contract assets restricted casha current assets december dollars millions equity investments operating leases inventories pension postretirement research development restricted casha receivables convertible notes noncurrent assets restricted cash consists funds restricted annual company contributions defined contribution plan us escrow litigation settlements cash restricted withdrawal general use contractually legally restricted december dollars millions rebates discounts income taxes employee compensation benefits research development dividends interest royalties operating leases current liabilities december dollars millions income taxes pension postretirement operating leases deferred income deferred compensation noncurrent liabilities note equity accumulated capital excess common stock treasury stock par value comprehensive retained noncontrolling dollars shares millions shares par value stock loss earnings shares cost interest balance december net earnings comprehensive incomeloss cash dividends declareda share repurchases stock compensation distributions balance december net earnings comprehensive incomeloss cash dividends declareda share repurchases stock compensation distributions balance december net earnings comprehensive incomeloss cash dividends declareda share repurchases stock compensation convertible debt distributions balance december cash dividends declared per common share bms share repurchase program authorized board directors allowing repurchases shares effected open market privately negotiated transactions compliance rule b exchange act including rule b trading plans share repurchase program obligate us repurchase specific number shares specific expiration date may suspended discontinued time treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method generally funded cash hand december board directors approved increase billion share repurchase authorization bms 's common stock remaining share repurchase capacity bms share repurchase program billion december bms repurchased approximately million shares common stock billion bms entered asr agreements repurchased million shares common stock billion addition part share repurchase program bms repurchased million shares common stock billion bms entered asr agreements repurchased million shares common stock billion addition part share repurchase program bms repurchased million shares common stock billion asr agreements funded cash onhand total number shares repurchased asr agreements based volumeweighted average prices bms 's common stock terms asr transactions less discount subject adjustments pursuant terms conditions asr agreements components comprehensive incomeloss follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedges recognized comprehensive incomeloss reclassified net earningsa derivatives qualifying cash flow hedges pension postretirement benefits actuarial gainslosses amortizationb settlementsb pension postretirement benefits marketable debt securities unrealized lossesgains foreign currency translation comprehensive incomeloss included cost products sold incomeexpense net refer note financial instruments fair value measurements information b included incomeexpense net accumulated balances related component comprehensive incomeloss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits marketable debt securities foreign currency translationa accumulated comprehensive loss included foreign currency net investment hedges gains million million december december respectively note retirement benefits bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans certain employees defined benefit pension plans net periodic benefit cost defined benefit pension plans million million million years ended december respectively changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows year ended december dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements curtailments actuarial gainslosses benefits paid foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid foreign currency fair value plan assets end year funded status assetsliabilities recognized noncurrent assets current liabilities noncurrent liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans billion billion december respectively additional information related pension plan follows december dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations follows december discount rate rate compensation increase interest crediting rate weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit cost follows year ended december discount rate expected longterm return plan assets rate compensation increase interest crediting rate yield high quality corporate bonds matching duration benefit obligations used determining discount rate ftse pension discount curve used developing discount rate us plans expected return plan assets assumption plan based managements expectations longterm average rates return achieved underlying investment portfolio several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets actuarial gains losses related plan benefit obligations primarily resulted changes discount rates postretirement benefit plans comprehensive medical group life benefits provided substantially bms us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory postretirement benefit plan obligations million million december respectively weightedaverage discount rate used determine benefit obligations december respectively net periodic benefit credits material plan assets fair value pension plan assets asset category follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds classified level within fair value hierarchy valued nav shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company transfers levels year ended december investments using practical expedient consist primarily multiasset funds redeemable either daily weekly monthly basis investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses individual plan investment allocations determined local fiduciary committees composition total assets pension plans december broadly characterized allocation equity securities debt securities investments contributions estimated future benefit payments company 's estimated annual contributions future benefits payments expected material savings plans principal defined contribution plan bristolmyers squibb savings investment program contributions based employee contributions level company match us defined contribution plan expense approximately million million million note employee stock benefit plans may shareholders approved stock award incentive plan plan replacing previous equity plans plan authorizes awards form incentive stock options nonqualified stock options stock appreciation rights sars restricted stock restricted stock units rsus dividend equivalents performance share units psus market share units msus stockbased awards december plan plan authorized grant equity awards plan provides million shares authorized grants plus shares recaptured upon forfeitures terminations awards previous equity awards plans subject adjustments accordance terms plan december million shares available award million equity awards outstanding stock options rsus msus psus shares generally issued treasury stock satisfy bmss obligations plan prior equity award plans plan executive officers employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term years plan provides granting sars whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock award 's exercise price bms grant stock options sars years ended december options outstanding years generally vested ratably four years options granted replacements options held celgene option holders upon acquisition celgene provided cliff vesting andor longer shorter vesting periods rsus granted executive officers employees subject restrictions continuous employment generally vesting occurs ratably three fouryear period grant date subject accelerated vesting specified circumstances stock unit right receive stock end specified vesting andor deferral period stock units voting rights bms grants nonforfeitable stock units nonemployee directors msus granted executive officers vesting conditioned upon continuous employment occurs ratably four years subject accelerated vesting specified circumstances number shares issued upon vesting msus determined based specified payout factor requiring market price per share specified measurement date least grantdate share price market condition awards granted prior attainment higher payout factor calculated share price measurement date divided share price award date results higher percentage payout msus maximum target number msus awards granted prior share price used payout factor calculated using average closing prices grant date measurement date nine trading days immediately preceding grant date measurement date psus granted executive officers threeyear performance cycle granted target number stock units subject adjustment number shares issued psus vest determined based achievement specified performance goals performance condition based bmss threeyear relative total shareholder return compound annual growth rate relative peer group companies market condition awards granted threeyear total shareholder return relative peer group companies prior range maximum target number psus vesting conditioned upon continuous employment occurs third anniversary grant date subject accelerated vesting specified circumstances stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates stockbased compensation expense follows year ended december dollars millions cost products sold marketing selling administrative research development incomeexpense net total stockbased compensation expense income tax benefita income tax benefit excludes excess tax benefits sharebased compensation awards vested exercised million million million following table summarizes stock compensation activity year ended december stock options rsus msus psus weighted weighted weighted weighted average number average number average number average number exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares millions options shares rsus fair value msus fair value psus fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december expected vest dollars millions restricted stock units market share units performance share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share rsus msus psus fair value awards vested rsus replacement awards rsus msus psus total intrinsic value stock options exercised fair value rsus approximates closing market price bmss common stock grant date adjusting units eligible accrual dividend equivalents fair value msus estimated grant date using monte carlo simulation fair value psus estimated grant date portion related relative total shareholder return measure using monte carlo simulation remaining portion based closing market price bmss common stock grant date adjusting units eligible accrual dividend equivalents taking account probability satisfying performance condition grant date following table summarizes significant outstanding exercisable options december weightedaverage number options remaining contractual life weightedaverage aggregate intrinsic value range exercise prices millions years exercise price per share millions outstanding exercisable aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december last trading day note legal proceedings contingencies bms certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers partners suppliers service providers licensees licensors employees shareholders among others matters may involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements legal proceedings significant bms believes could become significant material described bms believe matters except otherwise specifically noted material adverse effect financial position liquidity bms believes substantial claims andor defenses matters outcomes bms 's legal proceedings contingencies inherently unpredictable subject significant uncertainties assurance increase scope one pending matters future lawsuits claims government investigations legal proceedings material bms 's financial position results operations cash flows particular period furthermore failure successfully enforce bms 's patent rights would likely result substantial decreases respective product revenues generic competition unless otherwise noted bms unable assess outcome respective matters able estimate possible loss range losses could potentially result matters contingency accruals recognized probable liability incurred amount related loss reasonably estimated developments legal proceedings matters could cause changes amounts previously accrued evaluated reporting period discussion bmss tax contingencies see note income taxes intellectual property eliquis europe lawsuits filed generic companies various countries europe seeking revocation compositionofmatter patents spcs relating eliquis trials preliminary proceedings held certain cases croatia october bms filed request commercial court zagreb preliminary injunction prohibit teva offering storing selling generic eliquis products croatia decision pending finland court granted request preliminary injunction prohibiting teva offering storing selling generic eliquis products finland obtained price reimbursement trial regarding teva 's challenge validity finnish compositionofmatter patent related spc concluded july decision pending france trial held regarding teva 's challenge validity french compositionofmatter patent related spc decision issued june confirming validity rejecting teva 's claims teva appealed decision ireland court granted request preliminary injunction prohibiting teva making offering putting market andor using andor importing stocking aforesaid purposes generic eliquis products trial court 's preliminary injunction decision subsequently affirmed appeal irish court appeal trial regarding teva 's challenge validity irish compositionofmatter patent related spc concluded july decision delivered december irish trial court found irish compositionofmatter patent related spc invalid bms intends appeal irish trial court 's decision netherlands requests preliminary injunctions prevent atrisk generic launches sandoz stada teva prior full trials validity dutch compositionofmatter patent spc initially denied lower courts however judgment issued august dutch court appeal overturned decisions lower court issued preliminary injunctions sandoz stada teva ordered companies recall generic eliquis product dutch market trials regarding challenges brought sandoz teva respectively validity dutch compositionofmatter patent related spc took place october january decisions pending norway trial held regarding teva 's challenge validity norwegian compositionofmatter patent related spc decision issued may confirming validity rejecting teva 's claims teva appealed decision hearing appeal scheduled april portugal patent validity infringement proceedings pending multiple companies seeking market generic versions eliquis trial regarding mylan 's challenge validity portuguese compositionofmatter patent scheduled commence february early september teva launched generic eliquis product portuguese market september company filed request preliminary injunction teva portuguese intellectual property court romania request preliminary injunction teva initially denied lower court however january romania court appeal overturned decision lower court issued preliminary injunction teva prohibiting teva offering storing selling generic eliquis products romania spain trial regarding teva 's challenge validity spanish compositionofmatter patent related spc held october decision delivered january spanish court found spanish compositionofmatter patent related spc invalid bms intends appeal spanish court 's decision sweden trial held regarding teva 's challenge validity swedish compositionofmatter patent related spc decision issued november confirming validity rejecting teva 's claims teva appealed decision hearing appeal scheduled may switzerland trial regarding teva 's challenge validity swiss compositionofmatter patent related spc held november decision pending uk sandoz teva filed lawsuits seeking revocation uk compositionofmatter patent related spc bms subsequently filed counterclaims infringement actions combined trial took place february judgment issued april judge found uk apixaban composition ofmatter patent related spc invalid bms appealed judgment may court appeal upheld lower court 's decision october uk supreme court rejected bms 's application appeal following first instance decision uk generic manufacturers begun marketing generic versions eliquis uk addition challenges validity compositionofmatter patent related spc pending denmark italy poland czechia slovakia hungary bulgaria greece lithuania generic manufacturers may seek market generic versions eliquis additional countries europe prior expiration patents may lead additional infringement invalidity actions involving eliquis patents filed various countries europe inrebic us september impact biomedicines inc impact received notice letter teva notifying bms impact filed anda containing paragraph iv certification seeking approval generic version inrebic us challenging certain patents listed orange book inrebic response october impact filed patent infringement action teva us district court district new jersey january parties entered confidential settlement agreement case dismissed onureg us bms received notice letters accord healthcare inc accord msn laboratories private limited msn teva pharmaceuticals inc teva natco pharma limited natco respectively notifying bms filed anda containing paragraph iv certification seeking approval generic version onureg us challenging us patent nos ' patent ' patent fda orange booklisted formulation patents covering onureg expire respectively response bms filed patent infringement action accord msn teva natco us district court district delaware case msn trial scheduled begin september trial dates scheduled teva natco actions november bms accord entered confidential settlement agreement case accord dismissed february apotex inc filed request inter partes review ipr ' patent july uspto granted apotex 's request institute ipr ' patent discovery ongoing january parties entered settlement agreement inter partes review terminated plavix australia sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc subsequently changed name apotex genrxapotex august genrxapotex filed application federal court australia seeking revocation sanofi 's australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court australia granted sanofi 's injunction subsidiary bms subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated genrxapotex case august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid bms sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims genrxapotex appealed september full court held claims patent invalid march high court australia denied request bms sanofi hear appeal full court decision case remanded federal court proceedings related damages sought genrxapotex bms genrxapotex settled genrxapotex case dismissed australian government intervened matter seeking maximum damages million aud million plus interest would split bms sanofi alleged losses experienced paying higher price branded plavix period injunction place bms sanofi dispute australian government entitled damages trial concluded september april federal court issued decision dismissing australian government 's claim damages may australian government appealed federal court 's decision appeal hearing concluded february june appeal court issued ruling bms sanofi 's favor upholding lower court 's decision december australian government granted leave appeal decision high court australia revlimid us april celgene received notice letter amneal pharmaceuticals amneal notifying celgene amneal filed anda containing paragraph iv certifications seeking approval market generic version revlimid us response january celgene initiated patent infringement action amneal us district court district new jersey asserting certain fda orange book listed patents thereafter february parties entered confidential settlement agreement case dismissed sprycel us bms received notice letters xspray pharma ab xspray nanocopoeia llc nanocopoeia handa oncology llc handa zydus pharmaceuticals zydus notifying bms filed applications containing paragraph iv certifications seeking approval dasatinib product us challenging two fda orange booklisted monohydrate form patents expiring february bms filed patent infringement action xspray us district court district new jersey may bms filed patent infringement action nanocopoeia us district court district minnesota november bms filed patent infringement action handa us district court northern district california march minnesota court denied motion nanocopoeia filed seeking judgment based pleadings june bms entered confidential settlement agreement handa settling outstanding claims litigation september bms entered confidential settlement agreement xspray settling outstanding claims litigation october bms entered confidential settlement agreement nanocopoeia settling outstanding claims litigation october bms filed patent infringement action zydus us district court district new jersey zeposia us october actelion pharmaceuticals ltd actelion pharmaceuticals us inc actelion filed complaint patent infringement united states district court district new jersey bms celgene alleged infringement us patent ' patent complaint alleges sale zeposia infringes certain claims ' patent actelion seeking damages trial date scheduled pricing sales promotional practices litigation plavix state attorneys general lawsuits bms certain sanofi entities defendants consumer protection action brought attorney general hawaii relating labeling sales andor promotion plavix february hawaii state court judge issued decision sanofi bms imposing penalties total amount million million attributed bms sanofi bms appealed decision march hawaii supreme court issued decision reversing part affirming part trial court decision vacating penalty award remanding case new trial penalty determination new bench trial concluded october decision pending product liability litigation bms party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits bms also faces unfiled claims involving products abilify bms otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders cases filed state federal courts united states pursuant previously disclosed master settlement agreement settlement related court orders vast majority cases united states resolved dismissed eleven inactive cases remain pending state courts new jersey also eleven cases pending canada four class actions seven individual injury claims two active certified class actions quebec ontario onglyza bms astrazeneca codefendants product liability litigation related onglyza plaintiffs assert claims including claims wrongful death result heart failure cardiovascular injuries allege caused use onglyza february judicial panel multidistrict litigation ordered federal onglyza cases transferred mdl us district court eastern district kentucky significant majority claims pending mdl others pending coordinated proceeding california superior court san francisco jccp jccp court granted summary judgment defendants march decision affirmed california court appeal california supreme court declined review decision july mdl court granted defendants ' motion exclude plaintiffs ' general causation expert january granted summary judgment august plaintiffs filed notice appeal december appeal remains pending sixth circuit part bms 's global diabetes business divestiture bms sold onglyza astrazeneca february potential liability respect onglyza expected shared astrazeneca securities litigation celgene securities litigations beginning march two putative class actions filed celgene certain officers us district court district new jersey celgene securities class action complaints allege defendants violated federal securities laws making misstatements andor omissions concerning trials ged celgene 's outlook projected sales otezla nda zeposia court consolidated two actions appointed lead plaintiff lead counsel coliaison counsel putative class february defendants filed motion dismiss plaintiffs ' amended complaint full december court denied motion dismiss part granted motion dismiss part including claims arising alleged misstatements regarding ged although court gave plaintiff leave replead dismissed claims elected dismissed claims dismissed prejudice november court granted class certification respect remaining claims march court granted defendants leave file motion summary judgment briefing completed june september court granted part denied part defendants ' motion summary judgment claims regarding statements made remaining officer defendants claims regarding celgenes corporate statements court denied defendants motion without prejudice granted defendants leave reraise issue october defendants filed motion partial summary judgment celgenes corporate statements april certain schwab management investment companies behalf certain schwab funds filed individual action us district court district new jersey asserting largely allegations celgene securities class action remaining defendants action schwab action july defendants filed motion dismiss plaintiffs ' complaint full march court granted part denied part defendants ' motion dismiss consistent decision celgene securities class action california public employees ' retirement system april calpers action dfa investment dimensions group inc behalf certain funds american century mutual funds inc behalf certain funds july respectively dfa action american century action gic private limited september gic action filed separate individual actions us district court district new jersey asserting largely allegations celgene securities class action schwab individual action remaining defendants actions october actions consolidated pretrial proceedings schwab action court also consolidated future direct actions raising common questions law fact schwab action consolidated schwab action october defendants filed motion partial summary judgment consolidated schwab action trial dates scheduled celgene securities litigations contingent value rights litigations june action filed bms us district court southern district new york asserting claims alleged breaches contingent value rights agreement cvr agreement entered connection closing bms 's acquisition celgene corporation november entity claiming successor trustee cvr agreement alleges bms breached cvr agreement allegedly failing use diligent efforts obtain fda approval lisocel breyanzi contractual milestone date thereby allegedly avoiding billion potential obligation holders contingent value rights governed cvr agreement allegedly failing permit inspection records response request alleged successor trustee plaintiff seeks damages amount determined trial relief including interest attorneys ' fees bms disputes allegations bms filed motion dismiss alleged successor trustee 's complaint failure state claim upon relief granted denied june february bms filed motion dismiss complaint lack subject matter jurisdiction october alleged former celgene stockholders filed complaint us district court southern district new york asserting claims behalf putative class celgene stockholders received cvrs bms merger celgene violations sections securities exchange act exchange act relating joint proxy statement action later consolidated another action filed court consolidated complaint thereafter filed asserting claims behalf class cvr acquirers whether bms merger celgene otherwise violations sections securities act securities act sections b exchange act complaint alleged february joint proxy statement materially false misleading failed disclose bms allegedly intention obtain fda approval lisocel breyanzi applicable milestone date cvr agreement certain statements made bms certain bms officers periodic sec filings earnings calls press releases investor presentations december november materially false misleading reason defendants moved dismiss complaint march court entered opinion order granting defendants ' motion dismissed complaint entirety claims sections securities act section exchange act dismissed prejudice claims sections exchange act dismissed leave file amended complaint plaintiffs filed april defendants moved dismiss amended complaint briefing motion completed june motion currently pending court november alleged purchaser cvrs filed complaint supreme court state new york new york county asserting claims behalf putative class cvr acquirers violations sections securities act complaint alleges registration statement filed connection proposed merger transaction celgene bms materially false misleading failed disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint asserts claims bms members board directors time joint proxy statement certain bms officers signed registration statement defendants moved stay action pending resolution federal action alternative dismiss complaint later filed similar motion response amended complaint february court granted defendants motion dismissed case entirety november alleged celgene stockholder filed complaint superior court new jersey union county asserting claims behalf two separate putative classes one acquirers cvrs one acquirers bms common stock violations sections securities act complaint alleges registration statement filed connection proposed merger transaction celgene bms materially false misleading failed disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint asserts claims bms members board directors time joint proxy statement certain bms officers signed registration statement celgene 's former chairman chief executive officer defendants moved stay action pending resolution federal action alternative dismiss complaint february court granted defendants ' motion stay declined reach merits defendants ' motion dismiss october plaintiff filed motion vacate stay trial dates scheduled cvr litigations litigation ira litigation june bms filed lawsuit us department health human services centers medicare medicaid services et al challenging constitutionality drugpricing program ira program requires pharmaceutical companies like bms threat significant penalties sell certain medicines governmentdictated prices august government selected eliquis program lawsuit bms argues program violates fifth amendment requires government pay compensation takes property public use requiring pharmaceutical manufacturers provide medicines third parties prices set government necessarily fall fair market value bms also argues program violates first amendment right free speech requiring manufacturers state agree price set government medicine 's maximum fair price determined negotiation even though true negotiation august bms filed motion summary judgment october government filed opposition bmss motion summary judgment crossmotion summary judgment thalomid revlimid litigations beginning november certain putative class action lawsuits filed celgene us district court district new jersey alleging celgene violated various antitrust consumer protection unfair competition laws allegedly securing exclusive supply contract alleged purpose preventing generic manufacturer securing supply thalidomide active pharmaceutical ingredient b allegedly refusing sell samples thalomid revlimid brand drugs various generic manufacturers alleged purpose bioequivalence testing necessary andas submitted fda approval market generic versions products c allegedly bringing unjustified patent infringement lawsuits order allegedly delay approval proposed generic versions thalomid revlimid andor allegedly entering settlements patent infringement lawsuits certain generic manufacturers allegedly anticompetitive effects plaintiffs behalf putative classes thirdparty payers sought injunctive relief damages various lawsuits consolidated master action purposes march celgene reached settlement class plaintiffs october court entered final order approving settlement dismissed matter settlement resolve certain claims certain entities opted settlement since filed new suits advancing related theories described certain consolidated coordinated suits described pending march humana inc humana opted settlement filed lawsuit celgene us district court district new jersey humana 's complaint makes largely claims allegations made settled thalomid revlimid antitrust class action litigation complaint purports assert claims behalf humana subsidiaries several capacities including direct purchaser indirect purchaser seeks among things treble punitive damages injunctive relief attorneys ' fees costs may celgene filed motion dismiss humana 's complaint april court issued order denying celgene 's motion dismiss order addressed celgene 's argument certain humana 's claims barred statute limitations court 's order address celgene 's grounds dismissal instead directed celgene present arguments renewed motion dismiss following filing amended complaints may humana filed amended complaint celgene bms asserting claims based additional factual allegations celgene bms subsequently filed motion dismiss humana 's amended complaint august september court held argument celgene bms ' motion trial date scheduled united healthcare services inc uhs blue cross blue shield association bcbsm bcbsm inc health care service corporation hcsc blue cross blue shield florida inc cigna corporation cigna molina healthcare inc molina several msp related entities msp recovery claims series llc mspa claims llc maomso recovery ii llc series pmpi segregated series maomso recovery ii llc msp recovery claims series llc msp recovery claims prov series llc msp recovery claims caid series llc together msp filed lawsuits making largely claims allegations made nowsettled class action litigation humana optout action uhs msp matters include additional claims related copay assistance thalomid revlimid cases pending us district court district new jersey bcbsm voluntarily dismissed claims celgene bms 's motion dismiss humana amended complaint applies actions well actions proceed described respect humana optout action trial dates scheduled may molina sued celgene bms san francisco superior court molina 's complaint makes largely claims allegations made settled class action litigation june san francisco superior court dismissed molinas claims molina later reasserted district new jersey described stayed remaining claims activity expected case disposition new jersey actions certain entities opted nowsettled class action also filed summonses related two actions philadelphia county court common pleas connection allegations made humana optout entities actions placed deferred status pending developments optout cases november certain specialty pharmacies filed action direct purchasers celgene bms certain generic manufacturers us district court district new jersey action makes largely claims allegations celgene bms made respect revlimid settled class action litigation seek injunctive relief damages sherman antitrust act also november putative class endpayor plaintiffs filed action celgene bms certain generic manufacturers us district court district new jersey class complaint brings claims based celgene 's allegedly anticompetitive settlements revlimid patent litigation seeking damages state antitrust consumer protection laws injunctive relief federal antitrust law celgene bms generic defendants filed consolidated motions dismiss two actions motions fully briefed may administratively terminated november pending ruling celgene bms 's motion dismiss humana amended complaint trial dates scheduled october november three healthcare systemsthe mayo clinic lifepoint corporate services gp intermountain health incfiled two new lawsuits celgene bms certain generic manufacturers making largely claims allegations celgene bms made respect revlimid nowsettled class action litigation seeking injunctive relief damages sherman antitrust act parallel state laws actions pending us district court district new jersey trial dates scheduled msk contract litigation april memorial sloan kettering cancer center eureka therapeutics inc collectively plaintiffs filed complaint bms celgene juno collectively defendants june plaintiffs filed amended complaint plaintiffs allege defendants breached license agreement allegedly failing use commercially reasonable efforts develop manufacture commercialize certain chimeric antigen receptor product failing pay plaintiffs running royalty least worldwide sales abecma allegedly owed plaintiffs license agreement defendants disagree plaintiffs ' claims filed motion dismiss amended complaint july january court granted defendants motion dismiss bms celgene removing case case juno continue trial date scheduled pomalyst antitrust class action september certain health plan entities filed action behalf putative class endpayor plaintiffs celgene bms certain generic pharmaceutical manufacturers us district court southern district new york class complaint asserts claims federal antitrust law state antitrust consumer protection unjust enrichment laws based allegations celgene bms engaged anticompetitive conduct related pomalidomide us including allegedly engaging fraud uspto acquisition patents related use pomalidomide filing alleged sham patent litigations generic pharmaceutical companies seeking market generic pomalidomide entering allegedly unlawful patent litigation settlements certain generic pharmaceutical companies seeking market generic pomalidomide december plaintiffs filed amended complaint added one individual pomalyst patient plaintiff removed generic manufacturer defendants added two individuals defendants trial date scheduled government investigations like pharmaceutical companies bms certain subsidiaries subject extensive regulation national state local authorities us countries bms operates result bms time time subject various governmental regulatory inquiries investigations well threatened legal actions proceedings possible criminal charges substantial fines andor civil penalties could result government regulatory investigations environmental proceedings previously reported bms party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity bms 's current former sites waste disposal reprocessing facilities operated third parties cercla remediation matters respect cercla remediation matters bms responsible various state federal international laws bms typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties bms accrues liabilities probable reasonably estimable bms estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties amount includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion financial statements audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising currentperiod audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate grosstonet us rebate accruals us medicaid medicare part managed healthcare refer note revenue financial statements critical audit matter description fully disclosed note financial statements company reduces gross product sales list price time revenue recognized expected chargebacks discounts rebates sales allowances product returns referred grosstonet gtn adjustments reductions attributed various commercial arrangements managed healthcare organizations government programs mandate various reductions list price chargebacks cash discounts reflected reduction receivables settled issuance credits customer rebates discounts adjustments reflected liability settled cash payments certain gtn liabilities related us medicaid medicare part managed healthcare organizations rebate programs gtn us rebate accruals involve use significant assumptions judgments calculation significant assumptions judgments include consideration legal interpretations applicable laws regulations historical claims experience payer channel mix current contract prices unbilled claims claims submission time lags inventory levels distribution channel given complexity involved determining significant assumptions used calculating certain gtn us rebate accruals auditing estimates involved especially subjective judgment critical audit matter addressed audit audit procedures related gtn us rebate accruals included following among others evaluated appropriateness consistency companys methods assumptions used calculate gtn us rebate accruals tested effectiveness internal controls review companys estimation model including underlying assumptions key inputs companys process calculate gtn us rebate accruals tested mathematical accuracy gtn us rebate accruals tested significant assumptions key inputs used calculate gtn us rebate accruals evaluated companys ability estimate gtn us rebate accruals accurately comparing actual amounts incurred gtn us rebate accruals historical estimates tested overall reasonableness gtn us rebate accruals recorded period end developing expectation comparison actual recorded balances involved audit professionals industry quantitative analytics experience assist us performing auditing procedures taxes unrecognized tax benefit liabilities us transfer pricing refer note income taxes financial statements critical audit matter description fully disclosed note financial statements company recognizes certain income tax benefits associated transactions us operating companies related foreign affiliates income tax benefits estimated based transfer pricing agreements thirdparty transfer pricing studies companys judgment whether morelikelythannot benefits realized tax benefits may ultimately realized company determined judgment accrued unrecognized tax benefit liabilities amounts recognized unrecognized tax benefit liabilities related us transfer pricing may significantly affected subsequent periods due various factors changes tax law identification additional relevant facts change companys judgment regarding measurement tax benefits upon ultimate settlement taxing authorities given complexity associated significant assumptions used judgments made calculate unrecognized tax benefit liabilities related us transfer pricing auditing estimates involved especially subjective judgment critical audit matter addressed audit audit procedures related unrecognized tax benefit liabilities related us transfer pricing included following among others evaluated appropriateness consistency companys methods assumptions used identification recognition measurement disclosure unrecognized tax benefit liabilities tested effectiveness internal controls review underlying assumptions key inputs companys process calculate unrecognized tax benefit liabilities obtained understanding companys related party transactions transfer pricing policies tested mathematical accuracy unrecognized tax benefit liabilities tested completeness unrecognized tax benefit liabilities tested reasonableness underlying tax positions amounts accrued selection unrecognized tax benefit liabilities reviewing companys evaluation relevant facts tax law associated tax position testing significant assumptions inputs used calculate unrecognized tax benefit liabilities reference third party data information produced entity understanding transfer pricing principles tax laws inquires management evaluated whether company appropriately considered new information could significantly change recognition measurement disclosure unrecognized tax benefit liabilities involved income tax specialists audit professionals industry experience assist us performing auditing procedures deloitte touche llp morristown new jersey february served company 's auditor since item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined exchange act rules ae de end period covered based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting defined exchange act rule af supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report form k issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information fourth quarter director officer company adopted terminated active rule b trading arrangement nonrule b trading arrangement term defined item regulation sk item c disclosure regarding foreign jurisdictions prevent inspections applicable report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion internal control financial reporting audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso also audited accordance standards public company accounting oversight board united states pcaob consolidated financial statements year ended december company report dated february expressed unqualified opinion financial statements basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp morristown new jersey february part iii item directors executive officers corporate governance reference made proxy statement section director nominees respect information relating directors incorporated herein reference made part hereof response information required item b information required item respect executive officers included part ia reliance general instruction g instruction item b regulation sk incorporated herein reference made part hereof response information required item c reference made proxy statement section govern governed codes conduct respect code ethics incorporated herein reference made part hereof response information required item reference made proxy statement section selected elected director succession planning identification board candidates shareholder nominations director respect procedures shareholders recommend nominees board directors incorporated herein reference made part hereof response information required item e reference made proxy statement section organized committees board respect audit committee incorporated herein reference made part hereof response information required item item executive compensation reference made proxy statement section executive compensation incorporated herein reference made part hereof response information required item except information executive compensation pay versus performance deemed incorporated reference herein item security ownership certain beneficial owners management related stockholder matters reference made proxy statement voting securities principal holders common stock ownership directors executive officers respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item b reference made proxy statement section items voted upon equity compensation plan information respect securities authorized issuance equity compensation plans incorporated herein reference made part hereof response information required item item certain relationships related transactions director independence reference made proxy statement section govern governed related party transactions respect certain relationships related transactions incorporated herein reference made part hereof response information required item b reference made proxy statement section selected elected director independence respect director independence incorporated herein reference made part hereof response information required item item principal accountant fees services reference made proxy statement sections items voted upon audit nonaudit fees items voted upon preapproval policy services provided independent registered public accounting firm respect aggregate fees billed us services provided principal accountant deloitte touche llp pcaob id incorporated herein reference made part hereof response information required item part iv item